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Abstract
Globally, group B   (GBS) remains the leading cause of sepsisStreptococcus
and meningitis in young infants, with its greatest burden in the first 90 days of
life. Intrapartum antibiotic prophylaxis (IAP) for women at risk of transmitting
GBS to their newborns has been effective in reducing, but not eliminating, the
young infant GBS disease burden in many high income countries. However,
identification of women at risk and administration of IAP is very difficult in many
low and middle income country (LMIC) settings, and is not possible for home
deliveries. Immunization of pregnant women with a GBS vaccine represents an
alternate pathway to protecting newborns from GBS disease, through the
transplacental antibody transfer to the fetus in utero. This approach to prevent
GBS disease in young infants is currently under development, and is
approaching late stage clinical evaluation.
This manuscript includes a review of the natural history of the disease, global
disease burden estimates, diagnosis and existing control options in different
settings, the biological rationale for a vaccine including previous supportive
studies, analysis of current candidates in development, possible correlates of
protection and current status of immunogenicity assays. Future potential
vaccine development pathways to licensure and use in LMICs, trial design and
implementation options are discussed, with the objective to provide a basis for
reflection, rather than recommendations.
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Introduction
Streptococcus agalactiae is also known as Lancefield’s group B 
Streptococcus (GBS), and is a Gram-positive diplococcus, origi-
nally known for causing bovine mastitis1. GBS remains the leading 
cause of neonatal sepsis and meningitis, and is associated with 
significant mortality and morbidity, including long-term neurode-
velopmental sequelae2. Disease risk is the highest during the first 
3 months of life3, the primary target for GBS disease control 
efforts, but risk of invasive GBS disease increases again later in life, 
in particular among pregnant women and adults with underlying 
conditions or older age1.
Neonatal infections (sepsis and pneumonia) contribute importantly 
to deaths among children under 5 years of age globally, with the 
highest rates in low income countries, followed by middle income 
countries4. The etiologies of neonatal infections in low income 
countries are poorly characterized but GBS likely contributes to 
this burden. A recent systematic review showed that neonatal GBS 
disease incidence and case fatality rates are highest among coun-
tries in sub-Saharan Africa. However, published data from this 
region remain sparse and the estimated numbers are still considered 
underestimates3. In high-income countries, GBS emerged as a 
leading cause of neonatal infection in the 1970s for reasons that 
remain poorly understood. Many resource rich settings have 
experienced significant reductions in the incidence of early-onset 
disease (onset of disease during days 0–6 of life) after introduc-
tion of targeted administration of intrapartum intravenous antibi-
otics to women at risk of transmitting GBS to their newborns5,6. 
However, this intrapartum prophylaxis has not proven to be effec-
tive in preventing late-onset disease (disease onset during days 7–89 
of life), and is not implemented in most high disease burden low-
and middle-income countries (LMIC). Therefore, there has been a 
longstanding interest in developing a maternal vaccine against GBS 
to prevent disease in infants of vaccinated mothers.
Among various vaccine candidates, the glycoconjugate vaccines 
targeting GBS capsular polysaccharide (CPS) have been most 
studied, although common protein vaccines hold the appeal of 
broader coverage against circulating disease-causing strains. GBS 
vaccine development underwent an active phase in the 1990s. 
Although pre-clinical and early clinical studies showed promise, 
efforts slowed for a period, for a variety of reasons, including the 
strong success of intrapartum prophylaxis in reducing the early-
onset disease burden in high income countries, and concerns about 
the acceptance and the liability coverages for maternal immuni-
zation. Recent years have experienced a wave of new activity in 
GBS vaccine development. Successes in rolling out pneumococcal 
conjugate, rotavirus, and Haemophilus influenzae type b vaccines 
to the world’s poorest countries through the GAVI alliance paved 
the way for future LMIC vaccine introductions. Finally there is 
a renewed interest in invigorating the maternal immunization 
platform, and several licensed products such as tetanus, influenza 
and pertussis vaccines are recommended for use among pregnant 
women in LMIC.
This review provides necessary background for non-GBS subject 
matter experts on issues of relevance to accelerating develop-
ment of a GBS vaccine for LMIC. It draws almost exclusively 
on published literature or public information but alludes to 
some key activities of relevance that are anticipating publica-
tions in the near future. First we provide an overview of GBS 
disease and the global burden with a focus on GBS disease in 
infants (days 0–90 days), the primary prevention target for a 
maternal immunization program. This is followed by a sum-
mary of GBS diagnostics, and a review of intrapartum antibiotic 
prophylaxis (IAP), standards of care, strategies and impact. The 
next three sections provide relevant background in GBS vaccine 
development including a brief review of GBS virulence factors, 
the history of GBS vaccine development, and a review of safety 
and immunogenicity of current vaccine candidates, primarily from 
phase II studies of a trivalent glycoconjugate vaccine formulation. 
This section also reviews issues related to measuring serologic 
endpoints and the current status of establishing immune correlates 
of protection. The final three sections address cost-effectiveness 
analysis and other potential contributions of mathematical mod-
eling to GBS vaccine decision-making; options regarding the 
planning and conduct of a phase III efficacy study; and different 
possible vaccine development pathways are presented. We 
conclude with a high level summary of key gaps in knowledge. 
Diseases and sequelae caused by GBS and 
population at risk 
Given the purpose of this document, information used in the next 
two sections (“Diseases and sequelae caused by GBS and popula-
tion at risk” and “GBS disease burden and serotype distribution”) is 
primarily from LMIC, supplemented with data from high-income 
countries whenever information from LMIC was not available.
Early-onset neonatal disease
Definition. Although definitions for early-onset neonatal disease 
vary, the most common include onset of GBS disease within 
72 hours of birth or days 0–6 of life7. See section on ‘Considerations 
for licensure based on immune markers’ for candidate definitions 
for a phase III trial.
Transmission. Early-onset disease is caused by vertical transmis-
sion through colonized mothers during or just before birth8. GBS 
can ascend from the vagina to the amniotic fluid after onset of labor 
or rupture of membranes9, although intrauterine infection with-
out evidence of ruptured membranes has been reported10,11. GBS 
in the amniotic fluid can colonize the fetal skin or mucus mem-
branes or can be aspirated into the fetal lungs, leading to an invasive 
infection12,13. Infants can also be exposed to GBS during passage 
through the birth canal and can become colonized at mucus mem-
brane sites in the gastrointestinal or respiratory tracts. It has been 
estimated that in the absence of any intervention, approximately 
50% of babies born to colonized mothers become colonized and 
1–2% of them progress to develop invasive disease14–16.
Risk factors. Risk factors for early-onset disease have been well 
described in resource-rich settings. A review of risk factors as estab-
lished in United States studies showed that the strongest risk factor 
for neonatal disease was a positive maternal vaginal culture at deliv-
ery (Odds Ratio [OR]: 204)17. Other risk factors include prolonged 
rupture of membranes, preterm delivery, GBS bacteriuria during 
pregnancy, birth of a previous infant with invasive GBS disease, 
maternal chorioamnionitis as evidenced by intrapartum fever, young 
maternal age, and low levels of antibody to type-specific capsular 
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polysaccharide antigens18–21. Although few risk factor analyses 
have been conducted in LMIC, epidemiologic characteristics of 
case series from these settings22–25, as well as a risk factor analysis 
of early-onset neonatal sepsis in South Africa26, suggest that the 
same risk factors play an important role in LMIC. Additionally, 
human immunodeficiency virus (HIV) infection in mothers has 
been shown to increase the risk of neonatal GBS disease. Recent 
studies from South Africa reported that HIV-infected women have 
lower GBS antibody concentrations and reduced transplacental 
antibody transfer compared to HIV-uninfected women27,28, and 
infants born to HIV infected mothers had lower anti-GBS surface 
binding antibody levels28. However, maternal HIV infection appears 
to be more of a risk for late-onset disease compared to early-onset 
disease.
Disease onset and clinical presentation. Most cases occur 
within the first 24 to 48 hours23,25,29–31, and more than half of 
early-onset disease occurs in term (≥37 weeks gestation) infants: 
studies from sub-Saharan Africa have reported the propor-
tion of pre-term infants among infants with early-onset disease 
to range from 10 to 46%22,24,25. Respiratory distress has been 
described as one of the most common presenting symptoms, 
ranging from 68% (South Africa, single hospital retrospective 
review, 1997–1999)25 to 83% (South Africa, surveillance at three 
secondary-tertiary care hospitals, 2012–2014)24. Early-onset 
disease most frequently manifests with bacteremia, and less fre-
quently with meningitis. A study in Malawi demonstrated that 
about half (52%) of children with early-onset disease presented 
with sepsis (defined as GBS isolated from blood with no clinical 
evidence of pneumonia), 17% with meningitis, and 14% with prob-
able meningitis (GBS isolated from blood and cerebrospinal fluid 
[CSF] findings consistent with meningitis)22. In the US, infants with 
early-onset GBS disease present primarily with bacteremia (80%), 
meningitis (6%), or pneumonia (7%)32. A recent study from Uganda 
suggests that neonatal GBS infection may be an under-recognized 
cause of cerebral hypoxic encephalopathy33, although more data 
are needed to confirm the nature of the link between the two.
Disease outcomes. Case fatality ratios reported in hospital-based 
studies from sub-Saharan Africa have ranged from 20% to 38%22,24,25, 
with higher case fatality among preterm infants24. A multi-country 
observational study conducted in Panama, Dominican Republic, and 
Hong Kong showed that the average number of days hospitalized 
ranged from 6 (Dominican Republic) to 15 (Hong Kong), with case 
fatality ratios ranging from 10% (Hong Kong) to 33% (Dominican 
Republic)34. Case fatality ratios in resource rich settings are nota-
bly lower (e.g., United States: 4–6%), yet a study from the United 
States reported a nearly eight times higher risk of death among 
preterm cases compared to term cases35.
Late-onset neonatal disease
Definition. Late-onset infections occur among infants aged 7–89 
days of life9,36. In some instances the period from day 3–89 is 
considered7.
Transmission. As with early-onset disease, development of 
late-onset GBS disease first requires adhesion of GBS to mucosal 
surfaces, followed by invasion across epithelial cells to gain entry 
to the bloodstream. Vertical transmission from colonized mothers 
can result in late-onset disease, although it is considered to play 
a less important role compared to early-onset disease37, and IAP 
has not impacted the late-onset disease burden in countries that 
provide IAP38. Nosocomial transmission, horizontal transmission 
from mother to infant after the perinatal period, and transmission 
from breast milk have also been described39–42, although it is unclear 
whether these are common routes of transmission38.
Risk factors. Risk factors for late-onset disease are less 
understood than those for early-onset disease, and prevention strat-
egies for late-onset infections have not yet been identified. Some 
of the identified risk factors are similar to those of early-onset dis-
ease, such as preterm delivery and maternal GBS colonization43,44. 
More recent studies have shown that preterm delivery may be a 
major factor for late-onset disease, with each week of decreasing 
gestation associated with an increased risk of late-onset disease44,45. 
Another prospective cohort study from Italy also showed that 
preterm infants had an increased risk for late-onset disease46.
As mentioned above, HIV exposure may be a greater risk for devel-
opment of late-onset disease compared to early-onset disease: one 
study from South Africa reported that the risk ratio of the incidence 
of GBS disease was 1.7 (95% CI: 1.3–2.2) compared to HIV- 
unexposed infants for early-onset disease vs. 3.2 (95% CI: 2.3–4.4) 
for late-onset disease47. Another South African study reported 
that the incidence of early-onset disease was similar between 
HIV-exposed and un-exposed (1.1 vs. 1.5; p=0.5) but there was a 
4.7-fold greater risk (95% CI: 2.3 vs. 0.5; p<0.001) for late-onset 
disease24. Similar results were reported from a study conducted in 
Belgium48.
Disease onset and clinical presentation. Studies reported 
different proportions of preterm infants (<37 weeks) among late-
onset cases: 49% in the United States38, 25% in South Africa24, 
and 14% in Malawi22, suggesting this proportion may be lower in 
LMIC than in high-income countries. A study from Italy showed 
that term infants develop disease earlier (median 23 days, 
interquartile range [IQR] 15–42) compared to preterm infants 
(median 39 days, IQR 28–58)46.
The proportion of infants with late-onset disease presenting with 
meningitis is higher compared to infants with early-onset disease, 
and data from sub-Saharan Africa reported that meningitis is 
one of the leading clinical presentations for late-onset disease 
(33–59%)22,24,25. Data from the United States show that about 26% 
of infants with late-onset disease presented with meningitis, while 
67% had bacteremia without a focus of infection38.
Disease outcomes. Because of the higher proportion of meningi-
tis cases among infants with late-onset disease, risk of long-term 
neurologic sequelae may be higher among survivors of late-onset 
disease compared with infants surviving early-onset disease49. A 
study from South Africa showed that GBS-affected infants were >13 
times more likely to have neurological sequelae at 6 months of age 
compared to controls, defined as abnormal Denver-II assessments 
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(in the following domains: gross motor, fine motor, language and 
personal/social) or presence of hypertonia or hyper-reflexia24. 
Results from the United Kingdom showed that 22% of survivors 
of neonatal meningitis (≤28 days of life) had mild to moderate 
sequelae (e.g., isolated hydrocephalus, isolated epilepsy, mild 
learning problems, mild cerebral palsy), and 14% had severe 
sequelae (e.g., cerebral palsy, global delay, significant learning 
problems) at 9–10 years of age50. Another multi-center study from 
the United States described similar percentages of neurologic 
sequelae among GBS meningitis survivors: 25% with mild-to 
moderate impairment, and 19% with severe impairment at a mean 
age of 7 (range 3–12) years2.
Reported case-fatality ratios are lower compared to those of early-
onset disease3,22,24,25,32. In the systematic review by Edmond et al., 
the pooled result of all studies reporting case fatality for early- 
onset disease was 12.1% (95% CI 6.2–18.3) and was 6.8% (95% 
CI 10.8–14.9) for late-onset disease. A more recent systematic 
review conducted by Sinha et al. reported that health facility-based 
studies from Malawi and South Africa reported case fatality ratios 
ranging from 20–38% for early-onset disease and 14–29% for late-
onset disease (meta-analysis was not done due to heterogeneity in 
numerator and denominator)51.
Other perinatal complications (preterm delivery, stillbirth)
Preterm delivery. GBS colonization during pregnancy has been 
associated with preterm delivery52,53, although the association is 
less clear than the association between colonization and early-onset 
disease. A systematic review which included 20 studies from 10 
different countries summarized results by study design: results 
from cross-sectional studies conducted at the time of delivery 
had a pooled OR of 1.75 (95% CI 1.43–2.14) for preterm deliv-
ery between GBS colonized mothers and non-colonized moth-
ers, and 1.59 (95% CI 1.03–2.44) for case-control studies that 
matched mothers with preterm delivery with mothers with the same 
gestational age, but not in labor. Whether colonization causes 
preterm delivery is still a matter of debate. A systematic review of 
cohort studies evaluating the odds of preterm delivery according 
to colonization status during pregnancy were inconclusive (pooled 
OR: 1.06; 95% CI 0.95–1.19)54.
Stillbirth. GBS has also been associated with spontaneous 
abortions and stillbirths. A retrospective study conducted in 
Australia which reviewed causes of spontaneous abortions 
(between 16 to 26 weeks gestation) among those with autopsy and 
microbiological cultures available showed that GBS was the most 
significant pathogen, often being the sole pathogen recovered, and 
found both in babies born to women with intact as well as ruptured 
membranes55. A study using United States population-based sur-
veillance data showed that 24% of invasive GBS infections during 
pregnancy resulted in septic abortions and/or stillbirths, a higher 
proportion than observed for pregnancy-associated invasive infec-
tions with Streptococcus pneumoniae (8%) or group A Streptococ-
cus (6%)56. Invasive GBS infections are however infrequent among 
pregnant women, whereas GBS colonization is much more common. 
Estimating the burden of GBS-related stillbirths is challenging, 
even in high income countries.
Maternal pregnancy-associated and postpartum GBS 
disease
GBS can cause urinary tract infection, chorioamnionitis, endometri-
tis, and bacteremia in women49. Women during pregnancy and 
shortly after are at a higher risk of developing invasive GBS disease 
compared to non-pregnant women of the same age group56. Data 
on pregnancy- and postpartum-associated GBS disease are limited, 
even in resource-rich settings, and we are not aware of data from 
LMIC. Data from United States population-based surveillance 
showed that GBS bacteremia without focus was the most common 
presentation both during pregnancy (43%) and the postpartum 
period (32%), followed by chorioamnionitis (33%) in pregnant 
women, and endometritis (25%) in postpartum56. Pneumonia and 
puerperal sepsis have also been reported35. Unlike influenza, inva-
sive GBS infection during pregnancy or the postpartum period 
was not associated with a longer hospital stay, an indicator of 
disease severity, or increased mortality risk, compared to non-
pregnant women56. Most (81%) of these pregnancy-associated 
invasive infections occurred in absence of additional underlying 
conditions35.
Vaginal GBS colonization is considered to be a risk for maternal 
chorioamnionitis and postpartum endometritis57,58. Some studies 
have suggested that GBS bacteriuria during pregnancy, possibly 
an indicator for heavy colonization59,60, may be associated with 
an increased risk for adverse obstetric outcomes, such as habitual 
abortion, intrauterine growth restriction, preterm labor, chorioam-
nionitis and premature rupture of membranes14,61. However, other 
studies have shown that asymptomatic GBS bacteriuria during preg-
nancy correlates poorly with GBS genital cultures at 35–37 weeks62 
or at delivery63. Both GBS vaginal colonization and bacteriuria are 
commonly asymptomatic among pregnant women.
Disease in non-pregnant adults
An increasing incidence of invasive GBS disease has been reported 
among non-pregnant adults in recent years, primarily from high-
income countries where surveillance for invasive GBS disease 
among all ages has been conducted35,64–67. Results from population 
surveillance from the United States showed a doubling of invasive 
GBS cases among non-pregnant adults (≥18 years) between 1990 
and 200767. The only multi-province surveillance for invasive GBS 
disease among non-pregnant adults in LMIC that we are aware of 
comes from Thailand, where GBS was the leading pathogen in an 
invasive bacterial diseases surveillance system68.
Skin- and soft- tissue infections are one of the most frequent 
clinical presentations in adults, although clinical syndromes 
associated with invasive GBS infections are variable, including 
bacteremia, pneumonia, bone and joint infections, urosepsis, endo-
carditis, meningitis, and intravenous catheter infections69. A study 
from South Africa showed that soft tissue abscesses and pneumonia 
accounted for 70% of the presentations and reported an overall 35% 
mortality among all identified GBS cases70. Another study from 
Malaysia showed that skin and soft-tissue infections accounted for 
>70% of all GBS infections71. The majority of disease occurs in 
people with significant underlying conditions, particularly diabetes 
mellitus. The proportion of subjects with diabetes reported in 
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population-based surveillance for invasive disease ranged from 20% 
in Canada72 to ≥40% in the United States of non-pregnant adults 
aged ≥15 years35,67. Estimates of the prevalence of diabetes among 
adults with invasive GBS infections from other countries come 
primarily from single institution studies, and vary from 28% in 
Soweto, South Africa to 71% in Malaysia64,70,71,73,74. Other conditions 
associated with increased risk of invasive GBS disease among 
non-pregnant adults include atherosclerotic cardiovascular disease, 
obesity, cancer, heart failure, and renal disease67. Age is also a risk 
factor; data from the United States, Europe and Thailand have 
shown that incidence rates for invasive GBS are highest among 
adults aged ≥65 years65–68.
GBS disease burden and serotype distribution
Challenges in estimating global disease burden
Quantifying the burden of neonatal GBS disease remains a chal-
lenge even in high-income countries: clinical characteristics are 
non-specific and often difficult to differentiate from non-infectious 
causes75. Invasive infections are most commonly diagnosed based 
on isolation of GBS from a normally sterile site (e.g., blood, cer-
ebrospinal fluid) in microbiological culture; however, sensitivity 
of blood culture varies depending on the bacterial load, blood col-
lection, and culture method, and typically requires 36 to 48 hours 
for positive results to become available75. Estimating GBS disease 
burden in LMIC is even more difficult: a portion of births may 
occur outside of hospital settings; facility-born infants may be dis-
charged quickly after birth; care seeking, particularly early in life, 
may be limited; access to care, particularly in rural areas may pose 
challenges; and health facilities may lack access to diagnostic tests 
or laboratory capacity or resources to diagnose GBS infection. As 
a result, particularly for early-onset disease, most of which occurs 
within the first 24–48 hours of life, GBS disease is likely under-
represented in studies from these settings76. Finally, incidence of 
neonatal GBS varies regionally3,14. IAP use should be considered 
in making regional comparisons, as IAP, an intervention known 
to reduce the risk of early-onset disease, is widespread in many 
resource-rich settings but rarely implemented in LMIC3.
As a result of these challenges, and the relative paucity of invasive 
disease data from LMIC, some researchers have focused on GBS 
colonization as a surrogate measure for neonatal disease. However, 
different studies in resource rich settings have reported similar 
and high maternal colonization prevalence but different neonatal 
disease incidence3,14, suggesting that the relationship between 
maternal colonization and newborn disease is not simple.
Estimating the invasive GBS disease burden in pregnant women 
is difficult due to the paucity of data from LMIC, and the com-
mon clinical practice of empiric treatment in absence of a definitive 
diagnosis for postpartum infections. Estimating the burden of GBS-
related stillbirths poses challenges even in high-income countries. 
First, there is inconsistency in the definition used for stillbirth. For 
international comparison, the World Health Organization (WHO) 
defines stillbirth as a baby born with no signs of life at or after 
28 weeks gestation77. However, various definitions of stillbirth have 
been used, making comparisons difficult between countries, or even 
within the same country78–80. In addition, stillbirths are not reported 
in national surveillance systems in about 90 countries80,81, and even 
where stillbirth is included in vital reporting systems, the causes of 
stillbirth are generally not recorded82. Diagnostic procedures may 
not be conducted or may not be available, and even if performed, 
there may be difficulties in producing valid results, as pathologic 
changes could have occurred before the time of investigation. 
Because GBS is a common colonizing organism of the birth canal, 
distinguishing the presence of GBS (for example in amniotic fluid 
or placenta or even fetal tissue) due to colonization from a direct 
role of GBS in fetal death adds further challenge in identifying the 
cause of death82.
Disease burden and serotype distribution by WHO region
Infants aged <90 days. Neonatal sepsis (in infants aged <1 month) 
is one of the leading causes of neonatal deaths globally83, and 
among the WHO regions, the burden is the highest in the African 
region, where it was estimated to cause 5.3 deaths per 1,000 live 
births in 201284.
A group at the London School of Hygiene and Tropical Medicine 
is updating the global GBS disease burden estimates, focusing 
on neonatal and maternal disease; results are expected in 2017. 
The most recent systematic review and meta-analysis currently 
available of invasive GBS disease in infants aged <90 days was 
published in 2012. This review showed that incidence of GBS 
disease was the highest in Africa (1.21 per 1,000 live births, 95% 
CI 0.50–1.91), followed by the Americas (0.67 per 1,000 births, 
95% CI 0.54–0.80), and lowest in southeast Asia (0.02 per 1,000 
live births, 95% Ci -0.03 to 0.07)3 (Table 1). While IAP is com-
mon in the Americas it is rarely used in Africa or Southeast Asia. 
Incidence of early-onset disease and late-onset disease was also the 
highest in Africa (0.53 and 0.24 per 1,000 live births, respectively). 
However, only four studies were available for incidence estimates 
in Africa (Kenya, Malawi, Nigeria, South Africa). A more recent 
systematic review based on additional studies from sub-Saharan 
Africa reported a somewhat higher estimated incidence of neonatal 
disease: 1.3 cases per 1,000 births for early-onset disease (Kenya, 
Malawi, Mozambique, Nigeria, South Africa, Zimbabwe) and 
0.73 per 1,000 births for late-onset disease (Kenya, Malawi, 
Mozambique, Nigeria, South Africa, Zimbabwe)51, although 
the authors believe this is still an underestimation of the actual 
incidence given the challenges in collecting data in these countries. 
A recent study of early-onset sepsis in Soweto, South Africa that 
used both blood culture and a real-time polymerase chain reaction 
test for GBS on whole blood estimated an incidence of early-onset 
GBS disease of 1.8 per 1000 live births, higher than the estimate 
of 1.3 per 1000 live births based on blood culture detections alone 
(Sithembiso Velaphi, SANISA study, in preparation). This differ-
ence underscores that invasive disease estimates from blood culture 
are minimum estimates unless they take into account blood culture 
sensitivity.
The low reported incidence of neonatal GBS disease from South 
Asia poses a puzzle: is this an accurate reflection of the disease 
burden, or is it a reflection of under-ascertainment due to the chal-
lenges of capturing specimens from ill newborns, particularly on 
day 0 of life, in this region? The Aetiology of Newborn Infec-
tions in South Asia (ANISA)85 study attempted to fill this gap by 
conducting population-based surveillance and etiologic evaluation 
Page 6 of 42
F1000Research 2016, 5:2355 Last updated: 25 MAR 2019
Table 1. Estimated GBS disease incidence among infants with disease onset 0–89 days, by region 
(adapted from 3).
Region (year of publication 
of included studies)
Countries included in review (number of studies) Pooled estimate of 
incidence per 1,000 
live births (95% CI)
Europe (2001–2011) Czech Republic (1), Denmark (2), France (1), 
Germany (1), Italy (1), Netherlands (2), Norway (2), 
Portugal (1), Slovakia (1), Spain (3), Sweden (1), 
UK (4)
0.57 (0.44–0.71)
The Americas (2002–2009) Antigua and Barbuda (1), Brazil (1), Jamaica (2), 
USA (12)
0.67 (0.54–0.80)
Eastern Mediterranean 
(2002–2009)
Iraq (1), Kuwait (1), Saudi Arabia (1), Tunisia (1) 0.35 (0.07–0.62)
Western Pacific (2004–2009) Australia (1), Australia and New Zealand (2), Macau 
(1), Malaysia (1), South Korea (1), Singapore (1)
0.15 (0.04–0.27)
Southeast Asia (2002–2009) Bangladesh (1), India (2), Thailand (2) 0.02 (-0.03–0.07)
Africa (2005–2009) Kenya (1), Malawi (1), Nigeria (1), South Africa (1) 1.21 (0.50–1.91)
of possible serious infections among newborns <60 days of age 
in the community in catchment areas in Bangladesh, Pakistan and 
India86. The study faced some anticipated challenges in registering 
babies on day 0 of life (88% of all live births were enrolled in 
the surveillance and 74% of those enrolled were visited within 
24 hours) and in capturing specimens from babies who died, par-
ticularly on day 0 of life. The study nevertheless included samples 
from over 970 babies with possible serious infection onset on day 
0 of life. At all study sites, presence of GBS was assessed by blood 
culture, and by PCR on whole blood and PCR on nasopharyngeal/
oropharyngeal samples on both ill babies and healthy controls. 
Colonization was detected, providing evidence that GBS is present 
in this region, consistent with other studies in Bangladesh and 
India87. However, culture-confirmed infections were rare among 
babies with possible serious infection in the ANISA study; culture- 
confirmed GBS infections were identified at the Sylhet site 
(Bangladesh) and Vellore site (India). Fuller results are under 
preparation for publication.
Edmond and colleagues reviewed available data on global sero-
type distribution. Serotype III accounted for almost half of all iso-
lates, followed by serotypes Ia, Ib, II, and V, and, this trend was 
similar across all WHO regions. Five serotypes (Ia, Ib, II, III, V) 
accounted for more than 85% of serotypes in all regions with avail-
able data: 98% in Africa, 96% in the Americas, 93% in Europe, 
89% in western Pacific, and 88% in the eastern Mediterranean3 
(Figure 1). However, serotype studies from low-income countries 
and Southeast Asia were not identified in this review (Table 2). 
Although not limited to neonates, a recent report from Vaccine Pre-
ventable Infections Surveillance conducted in Thailand sheds some 
light on serotype distribution of GBS disease in the southeast Asian 
region: among children aged <5 years with invasive GBS disease, 
serotype III was the most frequently isolated (approximately 50%), 
followed by Ia and Ib (approximately 13% each)88. In Edmond’s 
global review, the proportion of serotype III isolates was larger 
for late-onset compared to early-onset disease (53% vs. 37%)3 
(Figure 1). A more recent review from sub-Saharan Africa showed 
similar results: the five serotypes (Ia, Ib, II, III and V) accounted 
for 97% of early-onset disease and 98% of late-onset disease, and 
the proportion of serotype III was higher in late-onset cases (79%) 
than in early-onset cases (54%)51.
Maternal colonization. Ascertainment of maternal genital GBS 
colonization varies according to the specimens collected (e.g., 
vaginal sampling only vs. rectovaginal sampling), the culture 
medium, specimen transport and processing procedures and 
timing. In general, rectovaginal sampling has a higher yield than 
vaginal sampling only89,90, and use of selective broth media is 
better compared to nonselective blood agar89. A review estimated 
the prevalence of genital colonization in pregnant women to 
be around 13% globally, although included studies used various 
laboratory methods91. When restricted to studies which were con-
sidered to have used adequate methods (collection site including 
the vagina and using selective broth media), the estimated overall 
prevalence was 18% with regional variation: 12% in India/Pakistan, 
19% in Asia/Pacific, 19% in sub-Saharan Africa, 22% in 
Middle East/North Africa, and 14% in the Americas (no data from 
Europe included)91. Regional variation was also reported in a multi-
country cross-sectional study among pregnant women between 
20 and 32 weeks gestation which used a standardized labora-
tory method (specimens collected from the cervix, lower vaginal 
wall, and urine and used selective enrichment broth) and showed 
that overall colonization prevalence was 11%, ranging from 8% in 
Manila, the Philippines, to 22% in Philadelphia, United States, which 
may reflect geographic differences in disease burden92.
GBS colonization is known to fluctuate during pregnancy, and a 
recent longitudinal study in South Africa reported that acquisition 
rates and the duration of colonization differ according to GBS 
serotype93. Serotype distribution in colonized mothers may not 
correlate directly with serotypes causing invasive neonatal disease, 
as invasiveness appear to be different according to GBS serotype94. 
However, colonization data may provide some insight into circulat-
ing GBS serotypes in regions where data from invasive disease are 
limited, especially Southeast Asia. A recent systematic review from 
sub-Saharan Africa showed that serotype III (>30%), Ia and V 
(both >20%) were the most frequently isolated51. Another study that 
took place on the Thai-Myanmar border showed that serotype II 
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Figure 1. Global distribution of GBS serotypes by WHO region and disease onset, 1980–2011 (N=38 papers reviewed in total)3. This 
figure has been reproduced with permission from Elsevier3. n indicates the number of articles included in the review for each region and 
disease category. 
Table 2. Summary of countries with serotype data available from neonatal GBS 
disease and serotype distribution, by WHO region (adapted from 3).
WHO region Number of serotype 
articles available out of 
a total of 38 (1980–2011)
Countries reporting serotype
Americas 9 (24%) U.S. (6), Canada (2), Argentina (1)
Africa 2 (5%) South Africa (1), Nigeria (1)
Southeast Asia 0 NA
Europe 19 (50%) Czech Republic (1), Denmark (3), 
France (2), Sweden (2), U.K. (2), 
Portugal (2), Germany (2), Netherlands (1), 
Israel (1), Romania (1), Finland (2)
Eastern 
Mediterranean
1 (3%) Morocco (1)
Western Pacific 7 (18%) Japan (5), Australia (1), Singapore (1)
was the most frequently isolated serotype (24%), followed by Ia, 
VI, III, and V95. Results from a multi-country study showed that 
overall, serotype III (17.8%) was the most frequently isolated 
serotype, followed by serotypes V (17%) and Ia (5%); however, 
serotype III was not isolated in two of the sites (Philadelphia, 
United States and Yangon, Myanmar), whereas serotype VII was 
the most frequently isolated serotype in Khon Kaen, Thailand, 
and was the only site that reported this serotype92. The GBS global 
serotype distribution appears more diverse than previously reported; 
a recent review of maternal GBS colonization showed significant 
heterogeneity across and within regions96. Additionally the modeling 
team led by the London School of Hygiene and Tropical Medicine 
is including a comprehensive review of maternal GBS colonization, 
risk of neonatal disease, neonatal disease incidence and impairment 
outcomes as part of their update of GBS disease burden estimates. 
They will also review data on GBS-related stillbirth, GBS-related 
preterm birth and review data on the association of GBS disease 
with neonatal encephalopathy.
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Pregnancy-associated GBS disease and stillbirths. As described 
above, few data are available on the incidence of invasive GBS 
disease among pregnant and postpartum women in low- and 
middle-income countries. A study from the United States showed 
that the incidence of invasive GBS disease was 0.04 (95% CI 
0.03–0.05) per 1000 women-years for pregnant women, 0.49 (95% 
CI 0.36–0.64) per 1000 women-years for postpartum women, and 
0.02 (95% CI 0.02–0.02) for non-pregnant women between the 
ages 15–44 years56.
A recent systematic review evaluated the incidence of GBS-related 
stillbirth (defined as at ≥20 weeks gestation most likely caused by 
GBS infection, as confirmed by a GBS-positive culture sample from 
the placenta and/or amniotic fluid and/or a normally sterile site)97. 
GBS-related stillbirth rates ranged from 0.04–0.9 per 1,000 births 
with highest reported from a small study in the United States11, and 
the proportion of stillbirths attributable to GBS infection ranged 
from 0 –12%97; however, the review was limited by inconsistencies 
in stillbirth definitions and diagnostic methods and the number of 
studies available that met the inclusion criteria, particularly those 
from low- and middle-income countries to assess the burden of 
GBS-related stillbirth worldwide. Stillbirth data from Kenya were 
recently published98, and data from South Africa are currently 
being evaluated and are expected to be available, soon. These were 
both prospective studies that attempted to capture meaningful 
specimens from stillbirths for diagnostics and that applied similar, 
although not identical case definitions for a GBS-related stillbirth. 
In South Africa, preliminary estimates suggest GBS-related 
stillbirth incidence may be similar to that of early-onset GBS 
disease incidence (personal communication, Dr. Shabir Madhi).
Disease in non-pregnant adults.Annual incidence rates have been 
reported primarily from North America and Europe, ranging from 
1.5 per 100,000 population (Spain, ages 21–100 years, 1992–1999)73 
to 7.3 per 100,000 population (United States, ages 18–105 years, 
2007)67, and the rates tend to be higher with increasing age35,66,67. 
A population-based surveillance of invasive bacterial infections 
conducted in Thailand between 2010 and 2013 showed that the 
average annual incidence of invasive GBS disease is the highest 
among those aged ≥70 years (23 per 100,000 population68, simi-
lar to incidence reported among adults aged ≥65 years in 2005 in 
the United States (25.3 per 100,000 population)35. As seen when 
evaluating GBS disease incidence in other age groups or GBS 
colonization, geographic variation has been noted in the serotype 
distribution: reports from North America shows that serotype V is 
the most frequently isolated serotype in adult GBS disease, repre-
senting approximately 30% of the isolates as opposed to 11% for 
serotype III67,72, whereas reports from Europe show that serotype 
V (approximately 20%) was less frequent compared to serotype 
III (25–30%)66,99. A surveillance report from Thailand shows that 
among adults aged 21 years or older, serotypes Ia, II, II, V and 
VI represented >90% of cases, with serotype III being the most 
common (approximately 48%)88.
Diagnosis and treatment of GBS disease
Diagnosis
This section summarizes clinical and laboratory methods com-
monly used for diagnosing GBS disease. For summary of case 
definitions used in published studies and discussion on candidate 
case definitions for phase III studies.
Newborns/Young infants
Clinical evaluation of sick children Integrated Management of 
Childhood Illness (IMCI) was developed jointly by WHO and the 
United Nations International Children’s Fund (UNICEF) to pro-
mote the accurate identification and appropriate treatment of com-
mon childhood illnesses at first-level health facilities in low-income 
countries, where health workers rely on patients’ history, and signs 
and symptoms to determine a course of management. Infants 
<2 months of age are assessed for signs of very severe disease: not 
feeding well, convulsions, fast breathing [≥60 breaths/min], severe 
chest indrawing, fever [≥37.5°C], low body temperature [<35.5°C], 
movement only when stimulated or no movement at all. These 
clinical syndromes which warrant urgent referral of young infants 
to hospitals are defined as possible serious bacterial infection 
(PSBI)100. Rates of PSBI among newborns young infants in LMIC 
can be very high (80 cases/1000 live births or higher)101. Even in 
the higher middle income country setting of South Africa, hospital 
admission for physician-suspected early-onset sepsis occurred at a 
rate of approximately 30 cases/1000 live births15. WHO guidance 
recommends that newborns presenting with signs of PSBI should 
be admitted to the hospital and blood cultures and lumber punctures 
should be obtained whenever possible before starting antibiotics102. 
Additionally, the United States Centers for Disease Control and 
Prevention (CDC) GBS prevention guidelines recommend a blood 
culture at birth for infants born to mothers with chorioamnionitis, 
even if the infant is well-appearing9.
IMCI has a separate set of algorithms for children 2 through 
59 months. Children are first assessed for general danger signs 
(unable to drink or breastfeed, child vomits everything, lethargic 
or unconscious, had convulsions or actively convulsing). If stiff 
neck or general danger signs are present in a child with fever, admin-
istration of antibiotics and urgent referral are recommended103.
Laboratory detection of invasive disease Confirmation of inva-
sive GBS disease requires isolation of GBS from a normally 
sterile site (e.g., blood, CSF), which is usually done by collect-
ing cultures. Automated blood culturing systems have improved 
the practice of blood culture: the automated system automatically 
detects microbial growth by monitoring microbial CO2 detec-
tion, and eliminates the need for manual inspection or examina-
tion. In addition, growth of aerobes and facultative anaerobes 
are promoted by agitating culture bottles104. However, a recent 
review reported that many studies from LMIC used manual culture 
methods, with lower GBS incidence rates compared to studies 
using automated culture methods105. Therefore, differences in the 
culture methodology used can result in variation in reported GBS 
disease burden.
Rates of culture-confirmed infection are typically an order of 
magnitude or more lower than rates of clinical sepsis, although the 
culture positivity rate varies according to the criteria for collect-
ing culture and how samples were collected. It is known that the 
likelihood of pathogen isolation increases with the quantity of 
blood submitted for culture, and for neonates, at least 0.5 to 1 ml 
of blood is recommended7,106. Because of the small blood volumes 
that can be obtained from newborns and young infants it is also 
important to use pediatric rather than adult blood culture bottles. In 
real use many cultures contain inadequate amounts of blood107,108. 
The yield of blood culture also varies with organism density in the 
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blood. A study in infants 0–2 months of age showed that about 
half of the cultures positive for GBS had a very low organism 
density (≤1.0 cfu/ml)109. Based on an estimate from a study 
comparing the yield of pathogens from blood culture using blood 
samples with various volumes and bacterial load, the sensitivity 
of blood culture to detect low-level GBS bacteremia (1.0 cfu/ml) 
could vary from 44% (0.5 ml collected) to 98% (2 ml)110.
CSF analysis by lumbar puncture is the gold standard to diag-
nose meningitis. It is considered that up to 23% of neonates with 
bacteremia will also have concomitant meningitis, and that up to 
38% of those with meningitis will have a negative blood culture7. 
Therefore, children suspected of meningitis should undergo lumbar 
puncture to assess the CSF whenever possible. Laboratory methods 
to identify GBS are summarized in Table 3. Cloudy CSF, elevated 
CSF leukocyte counts, low CSF glucose (e.g., < 1.5 mmol/litre 
or a ratio of CSF to serum glucose of ≤0.4), elevated CSF protein 
(e.g., > 0.4 g/litre), and positive Gram stain results indicate 
presence of meningitis, and treatment should be started immedi-
ately while awaiting culture results102.
Once bacterial isolates suggestive of GBS are identified, various 
laboratory methods including culture-based methods and high 
sensitivity latex agglutination tests can be used for GBS identifica-
tion (see Table 3). More recently, nucleic acid amplification tests 
(NAAT) (e.g., polymerase chain reaction) have allowed direct 
GBS identification from clinical samples. Some studies have used 
NAAT in addition to culture in order to improve the detection of 
cases.
Neonatal colonization It is estimated that about half of neonates 
exposed to GBS by their colonized mothers become colonized with 
GBS, and only a small proportion of those develop invasive disease. 
Neonatal GBS colonization results from exposure to and swallow-
ing of GBS-infected amniotic fluid or maternal vaginal secretions. 
External auditory canal cultures are more likely to yield GBS in 
the first 24 hours of life compared to other sites, and isolation of 
organisms from the ear canal is a surrogate for the degree of con-
tamination from amniotic fluid and vaginal secretions sequestered 
during the birth process. After the first 48 hours of life, throat and 
rectal sites are the best sources for detection of GBS, and positive 
cultures indicate true colonization (i.e., multiplication of organisms 
at mucous membrane sites), not just maternal exposure111.
Pregnant and postpartum women
Maternal colonization Maternal colonization can be assessed by 
collecting swabs from the vagina and the rectum from pregnant 
women9. Swabs are inoculated into a selective broth medium, and 
subcultured on to an agar plate for bacterial isolation. If enriched 
selective broth media is used, GBS can be determined faster 
(see Table 3).
Chorioamnionitis The diagnosis and reporting of chorioamnio-
nitis varies widely. Some consider histopathologic diagnosis as 
the gold standard112. Amniotic fluid sampling and culture can be 
used in the diagnosis of chorioamnionitis, however, diagnosis of 
chorioamnionitis is often made clinically due to challenges in access-
ing uncontaminated amniotic fluid or placenta for culture113,114. 
Culture of the fluid may be conducted, but may have limited clini-
cal utility due to the potential colonization of the amniotic fluid 
and the time it takes to obtain results114. In addition, the infectious 
etiology is often polymicrobial115. Fever in a pregnant women is 
the most important clinical sign of chorioamnionitis. Other key 
clinical findings associated with clinical chorioamnionitis include 
uterine fundal tenderness, maternal tachycardia (>100/min), 
fetal tachycardia (>160/min), and purulent or foul amniotic fluid113. 
The WHO reference material lists fever (≥38.0°C) in pregnant 
women with foul-smelling watery discharge after 22 weeks and 
abdominal pain as symptoms typically present among pregnant 
women with chorioamnionitis116.
Table 3. Laboratory methods for identification of GBS from specific sample types.
Sample type Accepted laboratory methods
Bacterial isolate Streptococcal grouping latex agglutination tests; DNA probe 
test (e.g., AccuProbe); nucleic acid amplification test; 
CAMP and hippurate tests (for presumptive identification); 
Chromogenic agars specific for GBS identification;  
MALDI-TOF MS
Colonization swabs 
       Enrichment broth 
       Bacterial isolation
 
Pigmented broth, DNA probe, latex agglutination, NAAT 
See bacterial isolate section above
CSF Bacterial culture and species identification (see bacterial 
isolate section above), latex agglutination test, NAAT
Blood Bacterial culture and species identification as above 
(automated blood culture methods preferred): gold standard; 
NAAT on whole blood: can increase detection yield but a low, 
non-zero portion of healthy controls also test positive by this 
method
CAMP: Christie, Atkinson, Munch, Peterson; GBS: group B Streptococcus; MALDI-TOF MS: 
Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry; NAAT: nucleic acid 
amplification test
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Endometritis. The diagnosis of endometritis is also often made 
clinically, and is often due to polymicrobial infection117. Clinically, 
endometritis presents as fever, uterine tenderness, abdominal pain, 
and a purulent lochia or a positive culture of endometrial fluid or 
tissue118. Positive blood cultures may help identify the bacterial 
etiology, as bacteremia may be present in up to 20% of women118. 
In the WHO clinical guidance, fever in women after childbirth 
with lower abdominal pain, purulent, foul-smelling lochia and 
tender uterus is described as signs and symptoms typically present 
in women with endometritis116.
Stillbirths. Identifying infection as a cause of stillbirth is chal-
lenging: it is often difficult to determine the cause of stillbirth, and 
organism isolation on the placenta or the surface of the fetus does 
not prove causality119. Pregnant women may be colonized with GBS, 
and could contaminate the fetus or the placenta after membrane 
rupture or vaginal contamination during delivery119. In a recently 
published systematic review of 17 studies of GBS-related stillbirths, 
diagnosis was made based on a range of laboratory methods: culture 
confirmation from placenta (eight studies), blood/CSF (12 studies), 
amniotic fluid (two studies), and internal organs (eight studies)97. 
Careful placental histologic examination and autopsy are consid-
ered to be more useful in identifying the cause of stillbirths119,120, 
and culture of fetal heart blood or fluid from uncontaminated fetal 
sites during autopsy may help identify the infectious cause119.
GBS typing methods
Serological methods. Serological classification of GBS is based 
on the identification of capsular polysaccharides and protein 
antigens121. Capsular polysaccharide is currently the most advanced 
glycoconjugate vaccine target, and currently ten serotypes have 
been described (Ia, Ib, II–IX). Several serological methods have 
been used for serotyping (e.g., Lancefield capillary precipitin 
method, double immunodiffusion122, coaggulutination123, enzyme 
immunoassay124, latex agglutination125). The Lancefield capillary 
precipitin method is considered as the “gold standard”1,122. One of 
the most common methods for capsular polysaccharide serologic 
typing is the latex agglutination method, using antibodies specific 
for the 10 recognized capsular polysaccharides126. In a recent report 
of a multicenter external quality assessment of molecular and 
serological typing conducted in 14 institutions in 13 European 
countries, the commercially available latex agglutination method 
was the most widely used typing method, with a typeability value 
(number of accurate results/total number of tests performed) of 
>90%121. Limitations of serological methods include failure to type 
an isolate (~4–9% are classified as non-typeable) due to lack of 
or low expression of capsular polysaccharide under experimental 
conditions, the presence of reversible non-encapsulated variants, or, 
although rare, expression of a new capsular serotype1,126. In addi-
tion, results are dependent on the quality of the antibodies used and 
on the experience of the laboratory126.
Molecular typing methods
Serotyping As an alternative to serological serotyping methods, 
molecular approaches based on the detection of capsular gene typ-
ing have been developed in recent years. Molecular methods include 
polymerase chain reaction (PCR) in conjunction with sequencing, 
hybridization, or enzymatic restriction cleavage pattern analysis, 
and multiplex-PCR approaches1,126–128. These molecular approaches 
are attractive because they have made it possible to assign a molec-
ular serotype to otherwise nontypeable isolates by serologic meth-
ods, and because they are reproducible, specific, easy to perform, 
and suited for capsular polysaccharide typing in large-scale epide-
miological studies1. However, PCR serotyping could potentially 
misclassify certain serotypes126. Also, PCR serotyping does not 
reveal if the capsular polysaccharide gene locus detected is actually 
expressed as a polysaccharide capsule126. Recently, Sheppard and 
colleagues have conducted whole genome sequencing to determine 
serotype with promising results129. Although the method currently 
may not be cost-effective merely for determining serotype129, the 
whole genome sequencing platform can be used to obtain geno-
typing data of the strains, as described below, as well as in depth 
analyses of strains within clonal complexes130.
Genotyping Molecular typing methods have been used for 
further characterization of GBS and are useful in distinguishing 
different GBS strains in epidemiological studies121. Examples of 
methods include restriction fragment length polymorphism 
(RFLP)131, pulsed-field gel electrophoresis (PFGE)132, multilocus 
sequence-typing (MLST)133 and more recently DNA microarray-
based typing134. Whole genome sequencing has also enabled the 
investigation of large and small scale genetic changes in compre-
hensive collections of GBS strains, thereby permitting enhanced 
understanding of the diversity of the organism135. See Box 1 for 
definitions of serotype, genotype, strain, and clonal complex.
Treatment
Newborns/young infants. IMCI recommends hospitalization and 
intramuscular or intravenous treatment of all infants meeting the 
case definition for PSBI136. The recommended antibiotic selection 
for management of “serious bacterial infection” and “meningitis” 
in infants aged <2 months is ampicillin and gentamicin (Table 4)102. 
To date GBS remains universally susceptible to beta lactam anti-
biotics so penicillin and ampicillin remain effective therapeutic 
agents. The 2010 CDC guidelines recommend providing antibiotic 
therapy pending culture results for well-appearing newborns whose 
mothers had suspected chorioamnionitis9. The WHO recommends 
providing prophylactic intramuscular (IM) or intravenous (IV) 
ampicillin and gentamicin in neonates with documented risk factors 
for infection (see Table 4)102.
Box 1. Definitions of serotype, genotype, strain, and clonal 
complex1,327
Serotype: type of antigenically variable polysaccharide capsule
Genotype: the genetic makeup of an organism or a group of 
organisms with reference to a single trait, set of traits, or an entire 
complex of traits
Strain: a single isolate of any bacterial population and any 
laboratory induced variants thereof
Clonal complex: a group of bacterial strains derived from a recent 
common ancestor that share many alleles at various phylogenetically 
informative loci. A clonal complex generally includes the ancestral 
genotype and strains with minor variation
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Table 4. Summary of recommended management of severe bacterial disease in young infants and perinatal infections in selected 
guidelines from the World Health Organization.
Prevention of neonatal infections
Give prophylactic antibiotics only to neonates with documented risk factors for infection102: 
    •   Membranes ruptures >18 hours before delivery 
    •   Mother had fever >38°C before delivery or during labor 
    •   Amniotic fluid was foul-smelling or purulent 
Give IM or IV ampicillin and gentamicin for at least 2 days and reassess; continue treatment only if there are signs of sepsis (or a positive 
blood culture)
Management of infants aged <2 months
Infants <2 months with any signs of very severe disease103: 
    •   Give first dose of intramuscular antibiotics (ampicillin 50mg/kg and gentamicin 5mg/kg [age <7 days] or 7.5mg/kg [age ≥ 7days]) 
    •   Treat to prevent low blood sugar 
    •   Refer URGENTLY to hospital 
    •   Advise mother how to keep the infant warm on the way to the hospital 
 
Serious bacterial Infection in infants <2 months102: 
    •   Admit to hospital 
    •   When possible, do a lumbar puncture and obtain blood cultures before starting antibiotics 
    •   For newborns with any signs of serious bacterial infection or sepsis, give ampicillin (or penicillin) and gentamicin as first-line 
antibiotic treatment* 
    •   If at greater risk of staphylococcus infection (extensive skin pustules, abscess or omphalitis in addition to signs of sepsis), give IV 
cloxacillin and gentamicin 
    •   The most serious bacterial infections in newborns should be treated with antibiotics for at least 7–10 days 
    •   If an infant is not improving within 2–3 days, change the antibiotic treatment or refer the infant for further management 
 
Meningitis in infants <2 months102: 
    •   The first-line antibiotics are ampicillin and gentamicin* for 3 weeks 
    •   Alternatively, give a third-generation of cephalosporin, such as ceftriaxone (50mg/kg every 12 h if <7 days of age and 75mg/kg 
after 1 week) or cefotaxime (50mg/kg every 12 h if <7 days or every 6–8 h if >7 days of age, and gentamicin for 3 weeks 
    •   If there are signs of hypoxaemia, give oxygen 
    •   If the infant is drowsy or unconscious, ensure that hypoglycaemia is not present; if it is, give 2ml/kg 10% glucose IV 
    •   Treat convulsions (after ensuring they are not due to hypoglycaemia or hypoxaemia) with phenobarbital 
    •   Make regular checks for hypoglycaemia 
*recommended ampicillin dose: 50mg/kg every 12 hours (first week of life) or every 8 hours (weeks 2–4 of life)
Management of children aged 2 months and older
Septicaemia102 
Laboratory: will depend on the presentation but may include 
    •   Full blood count 
    •   Urinalysis (including urine culture) 
    •   Blood culture 
    •   Chest X-rays 
Treatment: 
    •   Give IV ampicillin at 50mg/kg every 6 h plus IV gentamicin 7.5mg/kg once a day for 7–10 days; alternatively, give ceftriaxone at 
80–100 mg/kg IV once daily over 30–60 min for 7–10 days/ 
    •   Give oxygen if the child is in respiratory distress or shock 
    •   Treat septic shock with rapid IV infusion of 20ml/kg of normal saline or Ringer’s lactate. Reassess. If the child is still in shock (fluid-
refractory shock), start adrenaline or dopamine if available. 
 
Meningitis102 
Laboratory: 
    •   Confirm the diagnosis with a lumbar puncture and examination of the CSF. If the CSF is cloudy, assume meningitis and start 
treatment while waiting for laboratory confirmation. 
    •   Microscopy should indicate the presence of meningitis in the majority of cases with a white cell (polymorph) count <100/mm3. 
Confirmation can be obtained from CSF glucose (low: <1.5mmol/litre or a ratio of CSF to serum glucose of <0.4). CSF protein  
(high>0.4g/litre) and Gram staining and culture of CSF, where possible. 
    •   Blood culture if available 
Treatment: 
    •   Ceftriaxone: 50mg/kg per dose IM or IV every 12 hours; or 100mg/kg once daily for 7–10 days administered by deep IM injection or 
as a slow IV injection over 30–60 min, OR 
    •   Cefotaxime: 50mg/kg per dose IM or IV every 6 hours for 7–10 days, OR 
    •   When there is no known significant resistance to chloramphenicol and β-lactam antibiotics among bacteria that cause meningitis, 
follow national guidelines or choose either of the following two regimens: 
            ○   Chloramphenicol: 25mg/kg IM or IV every 6 h plus ampicillin: 50mg/kg IM or IV every 6 h for 10 days, OR 
            ○   Chloramphenicol: 25mg/kg IM or IV every 6 h plus benzylpenicillin: 60mg/kg (100,000 U/kg) every 6 h IM or IV for 10 days.
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Prevention of neonatal infections
Prevention of peripartum infections
Women with group B Streptococcus colonization100 
    •   Intrapartum antibiotic administration to women with GBS colonization is recommended for prevention of early neonatal GBS 
infection (conditional recommendation based on very low-quality evidence) 
            ○   Ampicillin or penicillin G should first be considered for treatment except where there are contraindications (e.g. allergy history) 
or GBS strain has been microbiologically shown to be penicillin-resistant 
            ○   This recommendation should be implemented within the context of local policy and guidance on screening for GBS 
colonization. 
 
Women in preterm prelabor rupture of membranes100 
    •   Antibiotic administration is recommended for women with preterm prelabor rupture of membranes (Strong recommendation based 
on moderate-quality evidence) 
            ○   Erythromycin is recommended as the antibiotic choice for prophylaxis 
 
Women undergoing elective or emergency caesarean section100,151 
    •   Routine antibiotic prophylaxis is recommended for women undergoing elective or emergency caesarean section. 
    •   For antibiotic prophylaxis for caesarean section, a single dose of first-generation cephalosporin or penicillin should be used in 
preference to other classes of antibiotics.
Managing fever in mothers during pregnancy and labor
Fever during pregnancy and labor116 
        Probable diagnosis: cystitis, acute pyelonephritis, septic abortion, amnionitis, pneumonia, uncomplicated malaria, severe/
complicated malaria, typhoid 
 
    Septic abortion 
    •   Begin antibiotics* as soon as possible before attempting manual vacuum aspiration 
 
    Amnionitis  
    •   Give a combination of antibiotics until delivery 
              -   Ampicillin 2g IV every six hours 
              -   PLUS gentamicin 5mg/kg IV every 24 hours; 
              -   If the woman delivers vaginally, discontinue antibiotics postpartum; 
              -   If the woman has a caesarean section, continue antibiotics and give metronidazole 500mg IV every eight hours until the 
woman is fever-free for 48 hours 
    •   If metritis is suspected (fever, foul-smelling vaginal discharge), give antibiotics 
    •   If newborn sepsis is suspected, arrange for a blood culture and antibiotics 
*give ampicillin 2g IV very six hours PLUS gentamicin 5mg/kg IV every 24 hours PLUS metronidazole 500mg IV every eight hours until 
the woman is fever-free for 48 hours 
 
    Chorioamnionitis100 
    •   A simple regimen such as ampicillin and once-daily gentamicin is recommended as first-line antibiotics for the treatment of 
chorioamnionitis. (Conditional recommendation based on very low-quality evidence)
Managing fever in mothers after delivery
Fever after childbirth116 
           Probable diagnosis: metritis, pelvic abscess, peritonitis, breast engorgement, mastitis, breast abscess, wound abscess, 
wound seroma or wound haematoma, wound cellulitis, cystitis, acute pyelonephritis, deep vein thrombosis, pneumonia, atelectasis, 
uncomplicated malaria, severe/complicated malaria, typhoid, hepatitis 
 
    Metritis  
    •   Transfuse as necessary. Used packed cells, if available 
    •   Give a combination of antibiotics until the woman is fever-free for 48 hours: 
              -   Ampicillin 2g IV every 6 hours 
              -   PLUS gentamicin 5mg/kg IV every 24 hours 
              -   PLUS metronidazole 500mg IV every eight hours 
If fever is still present 72 hours after starting antibiotics, re-evaluate and revise diagnosis 
 
    Postpartum endometritis100 
    •   A combination of clindamycin and gentamicin is recommended for the treatment of postpartum endometritis (Conditional 
recommendation based on very low-quality evidence).
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Pregnant and postpartum women. For treatment of cho-
rioamnionitis, the WHO recommends ampicillin and once-daily 
gentamicin100. A combination of clindamycin and gentamicin is 
recommended as first-line treatment of postpartum endometritis. 
Use of intrapartum antibiotic prophylaxis (IAP) to prevent early-
onset neonatal disease is described in further detail in section 
‘Prevention of perinatal GBS disease through intrapartum 
antibiotic prophylaxis’.
Antimicrobial susceptibility. Globally, GBS resistance to peni-
cillin G or ampicillin has not been reported. Thus, beta lactams 
are considered first-line antibiotics for GBS infection or IAP. 
However, isolates with increased minimum inhibitory con-
centrations to these antibiotics due to mutations in penicillin 
binding proteins have been reported primarily from Japan and 
North America137–141. Macrolide and/or clindamycin resistant 
strains have been increasing. There are limited invasive GBS 
antimicrobial susceptibility data available from LMIC. This 
largely reflects the relative paucity of invasive neonatal GBS 
disease surveillance from a majority of LMIC. A system-
atic review on community-acquired neonatal and infant sep-
sis in developing countries (Nigeria [4], Iraq [1], Bangladesh 
[2], India [4], Nepal [1], Tanzania [2], Malawi [1], Uganda [1], 
Philippines [1], Ethiopia [1], Mozambique [1]) showed that among 
GBS isolates from neonates, 100% were susceptible to penicillin, 
60% (95% CI 25–91%) were susceptible to chloramphenicol, and 
65% (95% CI 0–100%) to third-generation cephalosporins142.
Prevention of perinatal GBS disease through 
intrapartum antibiotic prophylaxis
Intrapartum antibiotic prophylaxis
In the 1980s, clinical trials and a large observational study demon-
strated that administration of intravenous ampicillin or penicillin 
during labor to mothers with certain risk factors for GBS trans-
mission was highly effective (efficacy estimates of 80–100%) at 
preventing invasive early-onset GBS disease143–145. Effectiveness 
estimates, although often somewhat lower than estimates from trial 
settings due to a portion of women receiving less than the opti-
mal prophylaxis duration (at least 4 hours of a beta lactam agent 
before delivery) or non-beta lactam agents, are consistent with trial 
findings146,147. Based on this evidence, penicillin or ampicil-
lin are often the first line agents recommended for prophylaxis, 
with cefazolin and in narrow instances clindamycin or vancomy-
cin as options for penicillin-allergic women. WHO recommends 
intrapartum antibiotic administration (first choice penicillin G or 
ampicillin) to women with GBS colonization based on observed 
clinical benefits for the neonates (see Table 4); however, the 
guideline development group acknowledged the challenges in 
implementing GBS screening and provision of IAP especially in 
low-resource settings100. WHO recommendations and feasibility in 
LMIC are further discussed in the two sections below.
Strategies for targeted intrapartum antibiotic prophylaxis
Because only a portion of women are at elevated risk of transmit-
ting GBS to their infants, universal prophylaxis of all deliveries is 
not an optimal strategy, particularly since antibiotic exposure is 
associated with low but non-zero risks. The most immediate risk 
is maternal anaphylaxis to penicillin which is estimated to occur 
in four per 10,000 to 4 per 100,000 recipients148. In resource-rich, 
hospital settings, anaphylaxis-related mortality is exceedingly rare, 
but in low and middle income countries risks for complications 
from anaphylaxis, even for hospital births, may be higher. While 
there is no risk for anaphylaxis in the newborn, due to the very low 
probability of previous antibiotic exposure and the lack of transfer 
of maternal IgE antibodies across the placenta, intrapartum antibi-
otics do impact the microbiome of the maternal birth canal and thus 
the microbiome acquired by the newborn, particularly for vaginal 
births. Some studies suggest microbiome alterations, particularly at 
the time of birth, may result in health impacts well past the newborn 
period, although these have not yet been substantiated and the risks 
have not been quantified149.
Two major strategies have been employed to limit the portion of 
women exposed to intrapartum prophylaxis to those at most risk 
of transmitting GBS9. The risk-based strategy identifies women for 
antibiotic prophylaxis based on presence of known risk factors for 
early-onset disease including maternal fever, prolonged rupture of 
membranes, preterm delivery, and previous birth to an infant with 
invasive GBS disease and detection of GBS bacteriuria during 
the current pregnancy. In different countries employing the risk-
based approach, variations may exist in the risk factors screened 
for, or in the thresholds used to identify risk, based either on 
local epidemiology or efforts to narrow the portion of women 
targeted for prophylaxis. Maternal fever is most commonly defined 
as ≥38°C and prolonged membrane rupture is often ≥18 hours. 
In contrast, the culture-based screening leads to identification of 
women with vaginal/rectal GBS colonization late in pregnancy, as 
a basis for antibiotic prophylaxis indication. Women who present 
at labor without a culture result are managed according to the risk-
based strategy. Variants of the culture-based screening strategy also 
exist across countries but most recommend screening at 35–37 
weeks gestation.
Both strategies have been documented to result in significant 
declines in invasive early-onset GBS disease, both in single 
hospitals and population-based analyses, in a range of resource-rich 
settings5. A population-based comparison of the two strategies in 
the United States found that the culture-based screening strategy 
was over 50% more effective than the risk-based strategy, primarily 
due to the high proportion of GBS positive women who received 
intrapartum prophylaxis and to the frequency of colonized women 
without any noted risk factors (18% of the delivering population in 
the United States)150.
Although current WHO recommendations do not specify a 
recommended approach for identifying women at risk, antibiotic 
prophylaxis (erythromycin) to women in preterm pre-labor rupture 
of membranes is recommended, as part of a strategy to improve 
the prognosis of infants with preterm birth (strong recommendation 
based on moderate-quality evidence)100. Antibiotic prophylaxis is 
not recommended for women in preterm labor with intact amniotic 
membranes nor for women with pre-labor rupture of membranes 
at term or near term (36 weeks gestation and above). The latter 
recommendation is based on the review of evidence from studies 
in women with duration of ruptured membranes less than 12 hours, 
and it is acknowledged that there may be a benefit from antibi-
otic prophylaxis in women with prolonged rupture of membranes 
(>18 hours)100,151.
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Feasibility in low- and middle-income countries
Neither of the above strategies were designed in the context of 
LMIC and both pose implementation challenges, particularly in 
low-income country settings. In low income countries, safe admin-
istration of intravenous antibiotics may not always be affordable 
or feasible, particularly for settings where births do not occur in 
hospitals. Even in instances where intrapartum prophylaxis may be 
feasible, identifying candidates for prophylaxis poses unique barriers. 
The risk-based strategy has the appeal that the key variables for action 
can be captured at the time a woman presents for labor. However, 
even in middle income countries such as South Africa, capture of 
these variables may prove challenging in a busy labor and deliv-
ery setting. For example, in a study of over 8000 deliveries at 
the main public hospital serving Soweto, South Africa, less than 
1% of women were noted as having intrapartum fever suggesting 
under-ascertainment15. Additionally, gestational age is not always 
known and clear distinctions between term and preterm deliveries 
may not always be straightforward. Moreover, because risk factors 
such as prolonged membrane rupture may evolve over the course of 
labor, prophylaxis may not always be administered to women who 
develop risk factors after admission. In resource-rich settings such 
as the United States, a lower proportion of women with risk factors 
have been noted to receive prophylaxis compared to GBS-colonized 
women150; this may prove even more challenging in LMIC where 
providers care for a higher patient load. Finally, more women 
in LMIC than in resource-rich settings may present to facili-
ties at a late stage in labor, leaving insufficient time for efficient 
prophylaxis.
While the risk-based strategy poses challenges, few LMIC are 
positioned to overcome the implementation and cost challenges 
associated with late antenatal screening. In particular, LMIC settings 
rarely have access to a high proportion of women at 35–37 weeks 
gestation, a strong microbiology laboratory network to process 
antenatal samples, and systems for effective communication of 
results to labor and delivery staff.
Non-vaccine alternatives to intrapartum antibiotic 
prophylaxis
To date, possible alternative to intrapartum prophylaxis have not 
proven effective. Chlorhexidine wipes of the birth canal during 
labor and the newborn at birth were evaluated in a large clinical trial 
South Africa with no evidence of efficacy against culture-confirmed 
or clinical neonatal sepsis15. Universal administration of intramus-
cular penicillin to newborns within 1 hour of birth is implemented 
at one large center in the United States152–154; however the lack of 
a concurrent control makes it difficult to interpret effectiveness 
or generalizability. This strategy also exposes all newborns to 
antibiotics. IM penicillin intrapartum does not achieve high enough 
concentrations rapidly enough, and antenatal use of oral or IM 
antibiotics have not shown impact146,155–157.
Virulence factors of GBS
GBS disease typically progresses from bacterial colonization, 
penetration of placental or epithelial barriers, and immune evasion 
preventing clearance of GBS from the bloodstream. In the case of 
meningitis, the ability to cross the endothelial blood-brain barrier 
is also needed158,159. GBS expresses a number of virulence factors, 
which play different roles in these steps (summarized in Table 5), 
but one of the most prominent and best-studied is the capsular 
polysaccharide (CPS), which protects the bacteria from opsoni-
zation and subsequent phagocytosis and intracellular killing160,161. 
Table 5. GBS virulence factors and their role in transition from colonization to invasive disease 
(adapted from 158).
Mechanism
Virulence factor Colonization Adhesion Invasion Immune 
evasion
Neurotropism
Fibrinogen binding protein A (FbsA) + +
Fibrinogen binding protein B (FbsB) +
Laminin binding protein (Lmb) + +
GBS surface adhesion (BsaB) + + (+)
Alpha C proteins (ACP) + + + +
Serine rich repeat proteins (Srr) + + +
Pili + + + + +
Hypervirulent GBS adhesion (HvgA) + + + (+) +
β-hemolysin/cytolysin (β-H/C) + + + + +
Capsular polysaccharides (CPS) +
Streptococcal C5a peptidase of 
GBS (ScpB)
+
GBS immunogenic bacteria 
adhesion (BibA)
+
Factor H +
IgA-binding beta-antigen +
D-alanylation +
Superoxide dismutase (SodA) +
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The type-specific CPS contains a terminal sialic acid, which is 
identical to a sugar epitope widely displayed on the surface of 
mammalian cells. Presence of this sialic acid terminal allows GBS 
to mimic the host cell structure and avoid immune recognition111,162. 
To date, 10 different CPS types (Ia and b, and II–IX) have been 
identified161,163,164.
More recently, multilocus sequence typing (MLST) analysis has 
shown that sequence type (ST) 17 is associated with enhanced 
invasiveness in neonates independent of capsular serotype although 
most ST17 isolates are CPS type III165. ST17 displays meningeal 
tropism, and has been referred to as the hypervirulent clone166.
It has been hypothesized that the GBS isolates causing invasive 
GBS disease in neonates worldwide emerged from a few success-
ful clonal lineages, and virulence factor identification to date has 
focused on elements common across these clones161. Factors under 
investigation to date include the C5a peptidase, the AlphaC-like 
surface protein family, the Sip-protein, and pilus islands, all of 
which have different roles in the infection process161, and have 
been investigated as vaccine targets. Pili mediate GBS resistance 
to cationic antimicrobial peptides (AMPs), which are compo-
nents of the host innate immune system that play a critical role in 
combating bacterial infections167, and also facilitate adherence and 
attachment of the pathogen to host mucosal cells. More recently, 
a surface-anchored adhesion protein called hypervirulent GBS 
adhesion (HvgA) was identified from comparative expression 
analysis between clones of different virulence. HvgA is consid-
ered to be a specific virulence factor of hypervirulent ST17168. In a 
manner similar to that of pili, HvgA mediates both colonization 
and invasion in the intestine, which appears to be a prerequisite for 
meningitis in the neonatal mouse model161.
GBS vaccine development
Biological rationale for a vaccine
Prevention of neonatal GBS disease has been the primary focus 
for GBS vaccine development. Most cases of early-onset neonatal 
and young infant disease occur within the first 24 hours. There-
fore, maternal immunization rather than direct vaccination of new-
borns is required to prevent neonatal and young infant disease. In 
animal models, passive immunization (e.g., transferring sera of 
animals exposed to GBS disease) and active immunization (e.g., 
mouse maternal vaccination-neonatal pup challenge model) have 
been shown to be protective against development of GBS disease 
(see below for details on animal models). In humans, transpla-
cental transfer of protective maternal antibodies against GBS was 
first reported by Baker and colleagues169. Their study showed that 
mothers whose infants developed invasive GBS disease from 
serotype III had significantly lower levels of serum IgG levels to 
CPS III compared to mothers whose infants were exposed to type 
III but did not develop disease. Subsequent studies reported similar 
findings with other GBS serotypes170,171 and the association of low 
maternal GBS CPS specific IgG levels and the risk of GBS disease 
in their infants was further described19. Attempts have been made 
to identify a threshold that would confer protection against GBS 
disease for vaccine development.
Maternal IgG is transmitted transplacentally to the fetus, mediated 
by the neonatal Fc receptor (FcRn): maternal IgG is endocytosed 
within placental syncytiotrophoblast cells and bound to FcRn in the 
acidic environment of the endosome, then released to the fetal side 
of the syncytiotrophoblast when exposed to physiological pH172,173. 
Results from phase I/II trials have shown that maternal immuni-
zation with glycoconjugate vaccines results in increased CPS- 
specific antibody levels in the infants which persists for about 
2 to 3 months174,175. Transfer of maternal IgG initiates at around 
17 weeks gestation, although most of the transfer occurs after 
33 weeks gestation176. Therefore, infants born before 34 weeks 
gestation are likely to have decreased amounts of IgG177.
A study by Baker et al. using data from the United States estimated 
that third trimester maternal immunization could prevent approxi-
mately 46% of all late-onset GBS infections, given that 63.3% of 
infants who developed late-onset disease were born ≥35 weeks 
gestation, and of those born ≥35 weeks gestation, approximately 
72% of infections occurred during the first 6 weeks of life176. This 
is based on the assumption that infants born ≥35 weeks gestation 
would have acquired sufficient concentrations of maternal antibod-
ies, which would protect the infant from GBS disease for the first 
6 weeks of their life (translating to two half-lives of antibody decay). 
The optimal timing of maternal immunization that would maximize 
protection against young infants requires further investigation.
Results from a phase II randomized controlled trial have shown 
that the III-TT vaccine delayed the acquisition of vaginal and rectal 
GBS III (NCT00128219)178. Another study reported an association 
between increased serum CPS IgG levels and reduced homotypic 
GBS rectovaginal acquisition179. If the vaccine reduces maternal 
colonization, maternal vaccination could further reduce the risk of 
neonatal disease by reducing exposure to GBS in the first months 
of life.
Newborn and young infant response to natural GBS 
infection
Opsonization, followed by phagocytosis (ingestion of invading 
microorganism) and intracellular killing are the main mechanisms 
of host defense against GBS infection180. Opsonization requires 
the deposition of specific antibody and complement on the bacte-
rial surface, and antibody and complement do not kill GBS in the 
absence of phagocytes181. Type III GBS-CPS was shown to prevent 
activation of the alternative complement pathway but this effect 
can be overcome by the presence of a sufficient amount of CPS 
antibody182,183.
Immaturity of the immune system makes neonates more susceptible 
to infections: neutrophils have a small storage pool at birth, and 
are less responsive to chemoattractants than later in life. Neonatal 
monocytes, which mature into macrophages, are impaired in their 
capacity for killing intracellular GBS184. Newborns have an impaired 
ability to form antibodies in general, and are particularly deficient 
in their ability to mount antibody responses against polysaccha-
ride antigens185. Altogether, their capacity for GBS CPS antigen- 
specific protection is determined largely by the placental transfer 
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of maternal IgG antibodies186. Therefore, the goal of maternal 
immunization is to induce GBS-specific antibody levels in the 
mother to achieve antibody levels in the child that would confer 
protection during the first 3 months of life.
Animal models
GBS disease models. Pre-clinical studies using animal models 
are important to obtain sufficient data on safety, immunogenicity 
and potential efficacy of candidate vaccines before proceeding to 
clinical trials. A wide range of animal models has been used to 
study GBS-host interactions and to provide means to test poten-
tial therapies and vaccine approaches. A sampling, rather than a 
comprehensive review, is provided below.
Mice have been commonly used to model GBS infections. The ear-
liest animal models studies of GBS infections date to the 1930s122. 
In later studies, intraperitoneal or intravenous models of GBS 
infection in adult or neonatal mice were developed to simulate 
human infections187,188. In some cases, oral inoculation has been 
used as a means of inducing systemic infection in mice189. Notably, 
in both mice and rats, there appears to be an age-related decrease in 
susceptibility to invasive GBS infection190,191.
A large number of other animal model systems have been 
explored, including chicken embryo192, rabbits193, sheep194–196, 
piglet197, and non-human primates198,199. Some of these models 
(especially the large animal models) have been used to provide 
insights that are difficult or impossible to study in mice. The 
sheep194–196 and piglet models197 are of particular relevance for 
the study of hemodynamic changes in host animals during GBS 
sepsis. Non-human primate models of GBS infection have been 
used sparingly, but they are of particular utility in modeling 
newborn infections and host responses in vivo198,199.
Animal models of GBS colonization. Fewer studies have used 
animals to model asymptomatic GBS carriage, despite the impor-
tance of the carrier state for maintenance of GBS in the population 
and the role of maternal colonization as the major risk factor for 
neonatal disease. Most recent work in this area has used murine 
models of vaginal or gastrointestinal colonization.
Vaginal colonization models have allowed determination of 
specific bacterial or host factors involved in carriage in the absence 
of invasive disease200–208. Gastrointestinal GBS colonization has 
been modeled in gnotobiotic mice and used as a means to under-
stand the role of surface proteins in GBS carriage209. Neonatal 
mice have also been used as a model for gastrointestinal carriage, 
especially as a prelude to invasive disease168. Oral colonization of 
infant rats has been used to examine the utility of antibiotics to 
decrease mucosal bacterial load210.
Animal models of ascending infection and/or perinatal GBS 
transmission. To examine the role of ascending infection in 
adverse pregnancy outcomes (e.g., preterm delivery, stillbirths), 
animal models simulating human infections have been explored. 
Examples include intracervical GBS inoculation of rabbits211–213, 
murine intravaginal/intrauterine/intraperitoneal inoculation214–216; 
catheterization and intraamniotic instillation of GBS has been 
used to model chorioamnionitis in non-human primates and to 
study its effects on fetal lung tissue217–220. However, initial attempts 
to create an ascending infection animal model secondary to 
chronic vaginal colonization, which is a better simulation of human 
infection, were unsuccessful213. Recently, Randis and colleagues 
have developed a model of GBS ascending infection during preg-
nancy secondary to vaginal colonization using pregnant mice. This 
model may shed light on the role of bacterial virulence factors 
such as beta-hemolysin/cytolysin in causing adverse pregnancy 
outcomes associated with maternal GBS colonization203.
Preclinical studies of GBS vaccines in animal models
a. Passive immunization Animal models have been used to 
examine the effect of antibody delivery (passive immunization) 
on invasive GBS disease in vivo. The first studies used generation 
of antibodies in rabbits followed by passive protection of mice 
exposed to systemic GBS infection122,221. Subsequent studies used 
hyperimmune serum or purified antibody preparations to provide 
protection to neonatal experimental animals199.
b. Active immunization Active immunization formulations used 
in experimental animals have included whole killed GBS, purified 
bacterial components (generally capsular polysaccharide or puri-
fied proteins), or conjugate vaccine preparations. Most studies have 
used systemic vaccination (intramuscular, subcutaneous, or intra-
peritoneal), though some investigations of mucosal vaccine delivery 
(intranasal, oral, rectal, or intravaginal) have been reported222–227.
Most vaccine studies have used protection from invasive infection 
as their outcome, but reports of potential effects of vaccination 
on GBS colonization have also been presented228. The most fre-
quently used model to evaluate the efficacy of GBS vaccines is the 
mouse maternal vaccination-neonatal pup challenge model. In this 
model, female mice are actively vaccinated, and their offspring are 
challenged with GBS229,230. Maternal IgG is transferred to the pups 
similar to maternal antibody transfer in humans, and most pups of 
mothers vaccinated with a range of conjugate formulations have 
survived challenge231,232. This model continues to be used to test 
new vaccine targets233–235. However, GBS strains isolated from 
human infections may be highly adapted to their human host, 
and results obtained from mouse models must be interpreted with 
caution236. For example, human GBS isolates may express 
surface proteins that specifically interact with the human hosts but 
not with other animals236–238. In addition, the shorter gestational 
period of mice (19–22 days) should be taken into account to meas-
ure the timing of vaccination and passive protection in neonates239.
The structure and function of antibodies induced by vaccination 
and the kinetics of maternal antibody transfer to the fetus are most 
similar between human and non-human primates. Baboon models 
have been used in preclinical GBS vaccine studies229,230,240. As in 
mouse models, these studies showed that GBS conjugate vaccine 
induced CPS-specific antibodies230,240, and there was a correla-
tion between maternal and infant baboon serum antibody levels230. 
Differences have been noted in the kinetics of antibody responses 
and waning between humans and baboons241.
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History of GBS vaccine development
Polysaccharide vaccines. GBS capsular polysaccharide (CPS) has 
been the primary target for vaccine development. In the 1930s stud-
ies demonstrated that CPS-specific rabbit sera could be used to pro-
tect mice against lethal challenge with GBS242. The first purified 
type III CPS vaccine underwent phase I testing in healthy adults 
in 1978243, and subsequently type Ia and II CPS vaccines were 
tested. Type II CPS was found to be the most immunogenic, while 
type Ia and III showed an immune response in about half of the 
recipients244. Most adults (nearly 90%) had very low serum concen-
trations of CPS specific antibodies before immunization, which was 
considered to indicate immunologic naivety to GBS polysaccha-
rides, and was a partial predictor for a poor immune response244,245. 
Favorable safety of CPS vaccines was shown on a small scale in 
non-pregnant adults and among pregnant women245,246, and infant 
antibody levels in cord serum correlated with maternal antibody 
levels at delivery246.
Glycoconjugate vaccines. Immunogenicity of polysaccharides 
is enhanced by covalent conjugation with a carrier protein. 
Glycoconjugate vaccines have been developed for Haemophilus 
influenzae type b (Hib), Neisseria meningitidis and Streptococcus 
pneumoniae. Unlike T-cell-independent B-cell activation by 
non-conjugated polysaccharide antigens, glycoconjugate vac-
cines have the potential to induce both B- and T-cell memory and 
produce a stronger and highly functional IgG response through 
antibody class switching160.
The first GBS glycoconjugate vaccine trial conducted in humans 
involved a GBS III CPS-tetanus toxoid (III-TT) glycoconjugate160,247. 
Healthy non-pregnant women were recruited and randomized to 
receive III-TT, type III CPS vaccine, or placebo247. Results showed 
that the highest dose of III-TT produced higher levels of type III 
CPS-specific antibody measured two weeks after vaccination, and 
that the proportion of recipients achieving a ≥4-fold rise in antibody 
concentration was higher among those who received III-TT com-
pared to those who received unconjugated type III CPS vaccine247, 
suggesting that the glycoconjugated vaccines are able to induce a 
more robust immune response compared to polysaccharide-only 
vaccines. Following this first trial, phase I trials of monovalent Ia, 
Ib, II and V-TT conjugates showed immunogenicity of a single dose 
suggesting no need for addition of an adjuvant241,248,249. In another 
randomized controlled study in healthy non-pregnant women, 
receipt of GBS III-TT was associated with protection against future 
acquisition of type-specific GBS colonization, with 36% vaccine 
efficacy for vaginal acquisition and 43% efficacy for rectal acqui-
sition compared to controls who received tetanus and diphtheria 
toxoids (clinicaltrials.gov NCT00128219)178.
To achieve broader coverage against the GBS serotypes caus-
ing disease in humans, several multivalent vaccines have been 
developed and tested in humans. The immune response in 
subjects who received a bivalent vaccine containing II-TT and 
III-TT glycoconjugates did not differ statistically from the antibody 
responses to monovalent vaccines250,251. Novartis (now GSK) has 
developed a trivalent (serotypes Ia, Ib, III) glycoconjugate vaccine 
conjugated to a CRM197 carrier and conducted several phase I and II 
clinical trials in healthy non-pregnant and pregnant women (clini-
caltrials.gov NCT01150123, NCT01193920, NCT01446289).
Initially, GBS vaccine studies have used tetanus toxoid (TT) as 
the carrier protein, but there have been concerns about possible 
immune interference and adverse events upon subsequent vaccina-
tion with TT-conjugated vaccines229,250. CRM197, a nontoxic mutant 
of diphtheria toxin (DT), is another carrier protein, and has been used 
in the investigational trivalent GBS vaccine that went through phase 
II studies (clinicaltrials.gov NCT01412801, NCT01446289)174,252. 
A study showed equivalent immunogenicity of CPS V-TT and CPS 
V- CRM197 against the target GBS antigen249.
While vaccines conjugated to TT (used in Menitorix®[MenC-TT/
PRP-TT, GSK]) and DT (used in Menactra®[Men ACWY-DT, GSK] 
and in Synflorix®[PCV10, GSK]) have shown to induce immunity 
against TT or DT, vaccines using CRM197 as the carrier protein 
(used in Prevnar13®[PCV13, Pfizer], Menveo®[MenACWY-CRM, 
GSK], investigational trivalent GBS vaccine [GSK]) have not 
shown to induce immunity against DT174,253. The interest of induc-
ing protection against tetanus through a TT-conjugated GBS 
vaccine could be considered where maternal and neonatal tetanus 
remain a concern.
Lastly, there have been concerns that use of CRM197 may interfere 
with responses to routine infant vaccines that use CRM197 as the 
carrier protein, such as PCV13, Hib, and MenACWY254–256. In addi-
tion, use of CRM197 may interfere with responses to routine diphthe-
ria vaccination in infants, but results from a phase II study did not 
show any evidence of interference174.
Protein-based vaccines. Polysaccharide-based vaccines typically 
only provide protection against CPS types included in the vac-
cine or closely related serotypes, and may be vulnerable to sero-
type replacement/switching. Therefore, efforts have been made to 
identify proteins common to all GBS as the basis of a vaccine that 
would confer broad protection against GBS250.
Until whole genome sequences of two GBS strains became avail-
able in 2002, only a limited number of proteins involved in GBS 
pathogenesis were identified as potential vaccine candidates250. Rib 
and alpha are among the GBS surface proteins that have been stud-
ied extensively as possible vaccine targets257,258. Recently, Miner-
vaX, a privately held Danish biotech company, has initiated phase I 
clinical trials with a protein vaccine based on a fusion of the 
N-terminal portion of two surface proteins, AlphaC and Rib (GBS-
NN) (NCT02459262)259. MinervaX expects that GBS-NN will 
protect against up to 95% of GBS isolates, given the broad expres-
sion of AlphaC and Rib as well as cross-reactive proteins259.
During the past decades, the application of recombinant DNA tech-
niques and the availability of complete bacterial genomes have 
allowed use of genome-based vaccinology to identify new protein 
vaccine candidates250. Investigators from GSK used reverse vacci-
nology to identify a conserved sequence encoding components of 
pili proteins on the bacterial surface. A vaccine based on a com-
bination of these proteins conferred protection against different 
GBS strains in a mouse model260. However, coverage against all 
GBS strains was not possible due to antigenic variation associated 
with the pilin subunits250,260. Structural vaccinology was success-
fully applied to design an optimized BP-2a protein, a subunit of 
the backbone protein of the GBS pili known to have high gene 
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variability250. The protective capacity of a BP-2a variant is 
restricted to a small region (D3), and each variant fused into a 
single recombinant chimeric construct expressed in Escherichia 
coli which conferred strong protection against all six strains 
expressing a BP-2a variant in challenged mice235.
Evidence for immune correlates of protection
GBS-specific antibody concentration and correlates of protection. 
Sero-epidemiological studies showed some evidence in favor of an 
association between low maternal GBS CPS specific IgG levels 
and the risk of GBS disease in offspring. Associations between 
maternal GBS surface-protein antibody concentrations and invasive 
disease in their infants have not been as clearly established: among 
the surface proteins studied so far (surface immunogenic protein 
[Sip], resistance to proteases immunity group B [Rib], AlphaC 
protein, BetaC protein, fibrinogen-binding protein A, GBS- 
immunogenic bacterial adhesion, and pilus-island surface protein 
antibodies), limited data suggest that antibodies against alphaC 
and Rib proteins may provide protection against invasive neonatal 
GBS disease258,261–265.
Evidence from sero-epidemiological studies. Most of the earlier 
studies comparing capsular antibody concentrations between cases 
and controls were done using a small sample size (e.g., ≈10–50 
cases total per capsular serotype). More recent studies with larger 
sample sizes (e.g., >50–300 cases total per capsular serotype) 
have attempted to identify a serotype-specific IgG level in moth-
ers that would confer protection against infant disease due to the 
same serotype266–269. A summary of studies published after 2000 
is shown in Table 6. Both studies by Lin and colleagues were 
case-control studies using data collected from multiple study 
sites in the United States266,269. Maternal and cord serum sam-
ples were collected from enrolled participants after delivery and 
antibody levels were compared between cases (neonates who devel-
oped early-onset disease and their mothers) and controls (neonates 
who remained healthy despite being colonized with the same serotype 
and their mothers). The case-control study by Baker and colleagues 
was also a multi-center study in the United States and compared 
maternal serum samples from cases (those whose infants developed 
early-onset disease due to specific serotypes) matched by age and 
ethnicity with those from controls (those who were colonized with 
the sample capsular serotypes but whose infants did not develop 
disease)267. The study by Matsubara and colleagues was conducted 
at a single institution in Japan and compared serum antibody lev-
els of pregnant women with serotype VIII colonization with stored 
serum samples from four mother-and-neonate pairs with early-
onset serotype VIII infection270. Dangor and colleagues conducted 
a matched case-control study in South Africa; cases were infants 
with laboratory-confirmed invasive GBS disease within <90 days of 
age, and controls were age-matched healthy infants, whose mothers 
were colonized with the same GBS CPS serotypes as cases. Mater-
nal and infant serum from cases were compared with those of con-
trols (or cord serum in case of controls of early-onset disease268.
The results showed that in general, there was an inverse relation-
ship between maternal serotype-specific IgG levels and the risk 
of their infants developing GBS disease (Table 6). Except for 
the studies by Baker and Dangor267,268, all studies used relative 
statistical measures to estimate thresholds, whereas the study by 
Baker and Dangor used Bayesian modeling to determine the thresh-
old. This method is considered to be robust using small sample 
sizes and does not depend on preselected reference values271. Only 
the study by Dangor et al. included late-onset disease and due to the 
small sample size, they were not able to assess correlates of protec-
tion separately for early-onset disease and late-onset disease268.
Functional antibody concentrations and other potential 
endpoints of relevance. While the above studies showed evidence 
of an association between antibodies and risk of invasive infection, 
some infants developed disease despite having high antibody levels. 
Measurement of functional antibodies rather than overall antibody 
concentrations may be important to shed further light on immune 
correlates of protection, as total antibody levels might include inac-
tive antibodies272–274. An example of this is the opsonophagocytosis 
killing assay (OPkA)182,275, which mimics the in vivo process of the 
killing of the bacterium by host effector cells following opsoniza-
tion by specific antibodies. Antibody-mediated bacterial killing has 
also been shown to protect infants from GBS disease and may be a 
more useful marker than purely measuring antibody quantity via an 
enzyme-linked immunosorbent assay (ELISA)-type assay267. Func-
tional antibody assessed by OPkA appears to correlate more closely 
with protection from GBS colonization, a precursor to disease in 
infants, than CPS-specific antibody concentration276. However, 
OPkA assays are laborious to perform and require large volumes of 
test sera. This is a critical issue in studies where sample volume is 
at a premium, such as in neonatal studies. Other assays, including 
an antibody-mediated complement C3b/iC3b deposition assay28,277 
have been developed that are less labor intensive and less variable 
as they do not rely on human phagocytes and require small serum 
volumes. Avidity assays have also been explored but results indi-
cate no significant difference in median avidity between antibodies 
induced by unconjugated or conjugated vaccines with a large range 
of values obtained for both vaccines278.
Status of assay and reagent standardization efforts
Different assay methods, antigen constructs and standard 
quantitation for serotype-specific antibody levels267,269 have made 
comparison across studies challenging272. Different specific anti-
body concentrations that could be associated with protection from 
disease have been defined. However, these vary across studies 
and by GBS serotypes (Table 6), and there has been significant 
controversy regarding appropriate laboratory methods to derive 
such thresholds reliably279.
Historically, the radioantigen binding assay (RABA) has been 
seen as the gold standard for the quantification of anti-GBS anti-
body as it measures antibody in its native state169. However, 
the RABA has low sensitivity towards the lower limit of quan-
tification and is unable to identify immunoglobulin of differ-
ent isotypes and subclasses as so offers an incomplete picture of 
immunoglobulin concentration. Several more sensitive isotype-
specific ELISA have subsequently been developed and have 
been used in the majority of vaccine studies to date; however, 
the estimated antibody concentration required to reduce the risk 
of GBS disease varied266,267,269,270,280–284.These assay methods vary, 
resulting in difficulties in extrapolating data between studies. 
More recently, studies have used Luminex or Bioplex platforms in 
order to improve the sensitivity and throughput of these assays and 
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allow multiplexing. However, none of these ELISA or Luminex 
assays provide information on the ability of the antibodies to 
neutralize GBS. Therefore, an ELISA alone may not be sufficient in 
predicting protective immunity from GBS infection272. A possible 
solution to this may be the development of an effective functional 
antibody assay that could be used as an in vitro correlate of protec-
tion, such as OPkA.
However, to achieve this goal for GBS, assay standardization is 
required for each GBS antigen of relevance and for each serotype 
(Table 6. It is also possible that proposed thresholds might vary 
depending on study population differences (e.g., higher prevalence 
of HIV positive patients in the study268). Efforts to standardize 
quantitative and functional immunoassays are needed for phase 
II and phase III GBS vaccine studies using immunogenicity 
endpoints.
Vaccine development pathway
The development of a GBS vaccine as considered here is unique in 
that the primary target population is pregnant women, as opposed 
to vaccines that WHO currently recommends in pregnant women 
(e.g., tetanus toxoid, inactivated trivalent influenza vaccine, acel-
lular pertussis vaccine) which were not developed nor licensed to 
target pregnant women285–287. The anticipated vaccine development 
pathway will likely begin with preclinical studies relying on animal 
models to assess the immunogenicity and safety of the product. 
Potential adverse outcomes in both mothers and their offspring are 
evaluated, including reproductive and developmental toxicity asso-
ciated with the product288. Upon favorable pre-clinical evaluation, 
first time in human studies are conducted in healthy adults. Phase I 
testing could start in non-pregnant women of childbearing age, in 
a limited number of participants (e.g., <100)288. Phase II studies 
of up to several hundred subjects per trial typically provide more 
information on common local and systemic reactions and immu-
nogenicity evaluations of dose range and dose schedule288. Evalua-
tion in pregnant women would typically only start upon favorable 
evaluation in non-pregnant women. In addition to adding to infor-
mation on adverse events among mothers, phase II trials in preg-
nant women can provide initial information about safety effects in 
newborns, as well as information about IgG antibody transfer ratios 
to the newborn and duration/decay of these antibodies over time 
(see following section on endpoints of relevance in immunogenicity 
studies). Phase III trials would typically have a large enough sam-
ple size to provide data supportive of licensure288. Phase III pivotal 
licensure studies most classically include a well-defined primary 
clinical endpoint, but alternative pathways to licensure are being 
discussed in the case of GBS vaccines, considering the possibility 
of establishing a regulatory acceptable immune correlate of pro-
tection. Post-licensure evaluations may play a critical role in char-
acterizing rarer safety events and effectiveness under real-world 
conditions, as well as in special populations of interest.
Safety of vaccination during pregnancy
Vaccines targeting maternal immunization during pregnancy must 
demonstrate favorable safety for the mother, the developing fetus 
and the newborn. Upon request by the WHO Strategic Advisory 
Group of Experts (the senior WHO vaccine governance board), the 
WHO Global Advisory Committee on Vaccine Safety (GACVS) 
recently reviewed safety data on existing vaccines for maternal 
immunization in pregnancy289,290. The GACVS concluded that there 
is no evidence of adverse pregnancy outcomes from the vaccination 
of pregnant women with currently licensed inactivated virus, bac-
terial, or toxoid vaccines. They concluded that pregnancy should 
not preclude women from immunization with these vaccines if 
medically indicated. As described in the previous paragraph, WHO 
currently recommends administration of tetanus toxoid, inactivated 
trivalent influenza vaccine, and acellular pertussis vaccine to 
pregnant women, although none of these vaccines were licensed 
for use in pregnant women285–287. Conjugate vaccines (either 
licensed or investigational), when conjugated with different car-
rier proteins (e.g., TT, DT, CRM197), as well as vaccine formula-
tions including alum and oil-in-water emulsions as adjuvants have 
been used in pregnant women, and favorable safety has been 
documented174,252,291,292. Further considerations on safety evaluation 
of GBS vaccine candidates are presented in following sections.
Current GBS vaccine candidates in development
Review of existing candidates
CPS-based vaccines have been the most extensively studied among 
vaccine candidates, and trivalent glycoconjugate vaccine candidates 
have gone through phase I and II trials. Currently, there are no 
plans for these trivalent vaccine candidates to move on to phase III 
studies.
GBS protein vaccines using other target antigens293 and polysaccha-
ride vaccines conjugated with different carriers (e.g., GBS80 pilus 
protein, peptide)233,294 have been tested in animal models. GBS-NN 
is undergoing phase I evaluation (NCT02459262). A summary of 
candidate vaccines is shown in Table 7.
Safety data from phase I and II studies
Non-pregnant women. Multiple polysaccharide and protein 
conjugate GBS vaccines have been tested in healthy non-pregnant 
women, although the number of volunteers included was usu-
ally small (e.g., ≤30 in each vaccine group). Earlier studies test-
ing vaccine dose-response have shown local pain or mild redness 
which seemed to be more frequent upon immunization with higher 
doses241,247,248. More recently, a phase Ib randomized, observer-blind 
and placebo-controlled trial of a trivalent (serotypes Ia, Ib, III) GBS 
CPS-CRM197 conjugate vaccine was conducted among healthy non-
pregnant women (NCT01150123)295. In this study, approximately 
40 women were enrolled in each vaccine group, which consisted of 
different dosing schedule (e.g., one dose vs. two doses) and differ-
ent use of adjuvants (no adjuvant, use of Al(OH)3, or MF59 [either 
half dose or full dose]). Results showed that local reactogenic-
ity was increased in those who received vaccines with adjuvants 
(range: 40–42% in placebo group, 75–88% in vaccine group with-
out adjuvants, 93–100% in those with Al(OH)3, 83–100% in those 
with half dose MF59, and 93–100% in those with full dose MF59); 
the proportion of solicited systematic reactions was less frequent 
(58–65% in the placebo groups, 50–85% across vaccine groups). 
Serious adverse reactions were similar among the vaccine and the 
placebo groups (5–11% in placebo group, 0–5% in vaccine group 
without adjuvants, 0–15% in those with Al(OH)3, 0–8% in those 
with half dose MF59, and 5–15% in those with full dose MF59), 
but none of them were considered related to vaccination, and there 
were no deaths or premature withdrawals due to adverse events 
(NCT01150123)295.
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Pregnant women and newborns. The first phase I trial that 
used a glycoconjugate vaccine among pregnant women was 
conducted with III-TT vaccine with a saline placebo control 
group175. A total of 30 participants were enrolled, and no vac-
cine-associated serious adverse events were observed. Mild to 
moderate pain at the injection site occurred in 70% of the vac-
cine recipients compared to 40% in placebo recipients; 10% had 
redness at the injection site in the vaccine group compared to 0 
in the placebo group. Obstetrical complications, mostly related 
to need for cesarean section or postpartum fever, occurred in 
35% of vaccine and 70% of placebo recipients. All neonates had 
an uncomplicated hospital course in both groups. Results from a 
phase II randomized, observer-blind, multicenter study using 
trivalent (Ia, Ib, III) GBS polysaccharide-CRM conjugate vac-
cine among pregnant women has been published recently 
(NCT01446289)174. A total of 86 women at 24–35 weeks gestation 
were enrolled, of whom 51 were assigned to the vaccine group. 
Reports of solicited adverse reactions were similar between the 
groups, with 54% of the vaccine group vs. 53% in the placebo 
group reporting at least one solicited reaction. Reported rates of 
systematic reactions were similar, although more participants in 
the vaccine group reported local adverse reactions (40% in the 
vaccine group vs. 24% in the placebo group). All women gave 
birth to single, live born neonates, and obstetric outcomes were 
similar between the two groups. No infant deaths occurred during 
the study period, and serious adverse events were reported in 24% 
of the vaccine and 31% of the placebo group infants.
Immunogenicity
Endpoints of relevance. The phase I/II trials using investiga-
tional trivalent GBS conjugate vaccines quantified GBS serotype- 
specific antibody levels using ELISA and reported as geometric 
mean concentrations (GMC) (NCT 01446289, NCT01150123, 
NCT01412801). None of these studies evaluated antibody func-
tionality, but earlier GBS conjugate vaccine studies reported 
Opsonophagocytic assay (OPA) evaluation175,241,247,248. An ongoing 
phase I trial of GBS-NN is using both ELISA and OPA to measure 
immunogenicity.
Evidence from Phase I and II trials
a. Non-pregnant women (NCT01193920, NCT01150123) A 
phase Ib/II trial in which 40 non-pregnant women received two 
doses of trivalent GBS vaccine (Ia, Ib, III, 20/20/20μg) showed 
that compared to the placebo group, the geometric mean concen-
tration (GMC) of antibody measured by ELISA a month after 
the second vaccination was significantly higher for all measured 
serotypes (serotype Ia 40 μg/mL in vaccine group vs. 0.88 in pla-
cebo group; serotype Ib 5.3 vs. 0.25; serotype III 11 vs. 0.61), and 
remained higher a year after the first dose (serotype Ia 15 μg/mL in 
vaccine group vs. 0.86 in placebo group; serotype Ib 5.28 vs. 0.4; 
serotype III 7.03 vs. 0.3) (clinicaltrials.gov: NCT01193920)296. 
In a study by Leroux-Roels and colleagues comparing vaccine 
groups with different antigen concentration, adjuvants, and dos-
ing schedule (NCT01150123)295, results showed that all vaccine 
groups had a higher GMC compared to placebo groups at both 
61 days and 361 days after vaccination; a higher dose level, the 
presence of aluminum hydroxide adjuvant or a second dose did 
not significantly increase antibody concentration. The exception 
was a higher GMC against serotype III one year vaccination in the 
group having received a second dose. When stratified by antibody 
concentrations at baseline, women who had undetectable antibody 
concentrations had lower antibody responses than those with 
detectable antibodies at baseline.
b. Pregnant women and newborn (NCT01446289) The 
aforementioned phase I trial using III-TT vaccine in pregnant 
women reported that 19 of 20 recipients had 4-fold increases in 
III CPS-specific IgG after vaccination relative to pre-vaccination 
levels, infant cord levels were approximately 70% of maternal 
values at delivery, and opsonophagocytic killing measured in sera 
Table 7. Development status of current vaccine candidates (adapted from 329).
Developer Candidate name/identifier Preclinical Phase I Phase II POC Phase III
NIH Tetanus toxoid-CPS 
conjugates: monovalent 
(multiple studies), bivalent 
(one study); CRM197-CPS 
conjugate: monovalent (one 
study)
X X X X (trial in 
pregnant 
women)
Novartis/GSK CRM197-CPS conjugate: 
monovalent (multiple), 
trivalent (several)
X X X X (trial in 
pregnant 
women)
Minervax N-terminal domains of the Rib 
ad AlphaC surface proteins
X X
Novartis/GSK Pilus proteins X
Various 
academic 
groups
Other protein(s) and/or 
protein-CPS conjugates
X
CPS: capsular polysaccharide, GSK: GlaxoSmithKline, NIH: National Institutes of Health, POC: proof of concept
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of infants born to vaccine- but not placebo-recipients persisted until 
2 months of age, suggesting the potential to protect against both 
early- and late-onset GBS infant disease175. A phase II placebo- 
controlled trial using a single dose of trivalent (Ia, Ib, III, 5/5/5μg) 
GBS polysaccharide-CRM197 conjugate vaccine administered to 
pregnant women at 24–35 weeks gestation was conducted in 
Belgium and in Canada (NCT01446289)174. Levels of antibodies 
against serotypes Ia, Ib, and III at delivery were respectively 16-, 
23- and 20-fold higher than pre-vaccination. Of note, those with 
baseline antibody concentrations below the lower limit of detec-
tion had lower antibody responses compared to those with higher 
antibody levels at baseline. Infants born to vaccinated mothers had 
significantly increased antibody levels at birth, which persisted 
above placebo group levels at least 3 months after birth. Antibody 
concentrations decreased after birth and by day 91 were 22–25% 
of the levels measured at birth but were still 5–8.5 fold higher 
than those observed in the placebo group. There was only one (2%) 
preterm infant in the vaccine group, and there was no clear rela-
tionship between time from vaccination to delivery and maternal or 
neonatal antibody concentrations at birth for any of the serotypes. 
GBS-specific antibody ratios between vaccinated mother and infant 
(calculated as the paired ratio between the GBS-specific antibody 
concentration measured in the cord blood of the neonate to those 
measured in maternal sera at birth) ranged from 0.68 to 0.81 across 
the three serotypes (serotype Ia: 0.81, serotype Ib: 0.77, serotype 
III: 0.68). Currently, an extension study is underway to examine the 
safety and immunogenicity of a second dose of the trivalent vaccine 
administered in non-pregnant women after a time interval close to 
inter-pregnancy interval (NCT02690181).
Safety and immunogenicity evidence among special 
populations
HIV-infected mothers and their newborns. A non-randomized 
phase II open-label study using the trivalent (Ia, Ib, III) GBS 
polysaccharide-CRM conjugate vaccine was conducted in Malawi 
and South Africa among 270 pregnant women aged 18–40 years 
between 24–35 weeks gestation with or without HIV infection 
(NCT01412801)252. There was no control group. Enrolment strati-
fication ensured that about half of the HIV-infected women were 
in a low CD4 cell count category [50–350 cells/μL] or high CD4 
cell count category [>350 cells/μL]. Results showed that immune 
response to vaccines as well as serotype-specific antibody levels 
in infants at birth were lower in HIV-infected mothers and their 
infants. In mothers, the fold change in antibody concentrations 
was higher for the HIV-uninfected group than the HIV-infected 
groups, and those with undetectable antibody levels at base-
line had lower antibody concentrations post-vaccination com-
pared to those with detectable antibody concentration at baseline. 
Transfer ratios (infant geometric mean antibody concentration 
in blood collected within 72 hours of birth divided by maternal 
geometric mean antibody concentration in blood collected at 
delivery) were similar across all three groups (0.49–0.72).
Rates of women reporting at least one solicited adverse reaction 
were highest in the HIV-uninfected group (67%), compared with 
HIV-infected women with a low CD4 cell count (44%) or high CD4 
cell count (59%). Local reactions (most frequently injection site 
pain) were reported by 18–39% of women across the groups, and 
systematic reactions were reported by 40–59% of women (fatigue 
and headache were most frequent). Adverse events were reported 
by 74–78%, of which 7–23% were deemed to be caused by study 
vaccination. None of the reported serious adverse events (reported 
by 28–32% of women) or adverse events reported in infants 
(41–49%) were deemed to be caused by vaccination.
Cost-effectiveness evaluation for low and middle 
income countries
GBS vaccine cost-effectiveness assessments may shed light on 
the potential investment case for GBS vaccines before phase III 
trials have been completed. Six analyses of GBS vaccine cost-
effectiveness have been published to date, including four before 
the current era of GBS vaccine development297–300 and two recent 
analyses301,302.
The older studies evaluated cost-effectiveness in resource-rich 
settings (three in the United States and one in the United Kingdom). 
These documented the value of variants of screening- or risk-based 
intrapartum prophylaxis compared to ‘doing nothing’ and also 
assessed the potential value for a vaccine with assumed efficacy 
levels against GBS disease-causing serotypes, either as a mater-
nal immunization strategy or as a vaccine delivered to adolescent 
females. The UK analysis300 found that if a vaccine was available, 
the most cost-effective prevention strategy would include vaccina-
tion of all pregnant women, in combination with IAP for all preterm 
deliveries and a subset of term deliveries with risk factors (19% of 
all women treated). This study also emphasized the need for addi-
tional information on key model parameters.
Two more recently published cost-effectiveness analyses301,302 
focused on the conjugate trivalent vaccine (serotypes Ia, Ib, III) in 
clinical development at the time, assuming a single dose of GBS 
vaccine would be recommended during each pregnancy. The Oster 
analysis evaluated the addition of universal vaccination of pregnant 
women to the screening-based IAP strategy in the United States. 
Assuming a vaccine cost of $100 per dose and 75% vaccine efficacy 
against included serotypes among term deliveries and a reduced 
efficacy among preterm deliveries, this analysis found that the 
cost-effectiveness of maternal immunization may be comparable 
to other recently approved vaccines in the United States. A CDC-
sponsored cost-effectiveness analysis for the United States is in 
progress, with results anticipated in late 2016.
The Kim analysis focused on the upper middle-income country of 
South Africa. This decision-analytic model simulated the natural 
history of GBS transmission from mothers to infants and com-
pared four strategies: do nothing, risk factor-based IAP, mater-
nal GBS vaccination, and vaccination plus risk factor-based IAP. 
National and hospital-based GBS prevention policies in South 
Africa are consistent with variants of the risk factor-based IAP 
approach, although group of women eligible is quite narrow and 
implementation is limited. This analysis assumed a vaccine price 
per dose of 10–30 U.S. dollars (USD) and vaccine efficacy against 
included serotypes of 50–90% among term infants with a reduc-
tion among preterm infants. The most influential parameters in 
one-way sensitivity analyses were vaccine price per dose and early 
onset GBS disease incidence. This analysis concluded that mater-
nal immunization would lead to important reductions in the burden 
of infant GBS disease and be considered very cost-effective (range 
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416–3,545 in 2010 USD/DALY averted comparing vaccination to 
doing nothing; range 461–5,491 2010 USD/DALY averted compar-
ing vaccination to risk factor-based IAP). Notably, vaccination plus 
risk factor-based IAP was more effective and consistently very cost 
effective. Risk factor based IAP alone was also very cost effective 
but prevented only a small burden of infant GBS disease.
Sinha and team are also in the process of conducting a GBS 
vaccine cost-effectiveness analysis for GAVI-eligible low-income 
sub-Saharan African countries. Thirty seven countries in the region 
were clustered into four groups based on 24 measures of economic 
development, general health resources, and past success in public 
health programs. A decision-analytic model was built to compare a 
natural history arm (‘do nothing’) with maternal immunization as 
part of antenatal care. Risk factor-based IAP was not included in 
this assessment due to expert opinion that this was not feasible for 
these low income birth settings. Results are expected in late 2016.
Mathematical modeling related to GBS vaccines
Mathematical models, can inform decision-making related to 
vaccine development and implementation in several ways. For 
example, disease transmission models can shed light on the impact 
of varying key aspects of vaccine delivery such as age at vacci-
nation, dosing schedules and method of delivery (e.g., vaccine 
campaigns versus incorporation into routine schedules). Models 
can also clarify the potential impact of a vaccine on unvaccinated 
members of the population (herd immunity) and predict potential 
unintended consequences of vaccine introduction such as an 
increased age at first infection, or the potential for replacement 
disease due to strains not included in the vaccine candidate. Finally, 
mathematical models can often highlight influential parameters 
where there would be value in a strengthened evidence base to 
allow for more accurate estimates.
In the context of maternal immunization for GBS, mathemati-
cal modeling to date is extremely limited. Some of the cost- 
effectiveness models developed have included a natural history arm 
that estimates disease burden based on a variety of maternal risk 
factors301. A non-dynamic compartmental model that estimates 
GBS-related outcomes based on maternal GBS colonization and 
risk of neonatal disease is under development as part of a global 
GBS disease burden estimation activity led by the London School 
of Hygiene and Tropical Medicine. It is possible that models could 
prove useful to better understand the impact of maternal vac-
cination timing on the preventable portion of newborn disease, 
particularly since earlier vaccination may offer protection to later 
preterm deliveries, depending on antibody transfer ratios and decay 
rates. If conjugate GBS vaccines have an appreciable effect on 
reducing acquisition of GBS colonization with vaccine-included 
serotypes, models may also help assessing the consequences of 
reduced exposure of the newborn to GBS. Models may also help 
predict the impact of maternal immunization across LMIC set-
tings with different prevalence of maternal HIV infection, levels 
of home vs facility deliveries, and optimal window for vaccination 
considering also antenatal care seeking behaviors. Models could 
contribute to the understanding of the potential impact of GBS 
vaccination on the burden of GBS-related stillbirth and preterm 
delivery.
Considerations about options to generate pivotal 
licensure data
The present document intends to provide an overview of available 
options and a framework for future reflection and should not be 
interpreted as guidance or recommendations.
Trial design options
Double-blind individually randomized controlled trial designs 
generate most robust data and minimize risks of bias. A relevant 
clinical endpoint288 supportive of efficacy evaluation provides the 
most direct evidence of the potential health impact. However, low 
baseline disease incidence may lead to very large sample size 
requirements for vaccine efficacy evaluation. A potential alterna-
tive option may be to use immunologic correlates of protection as 
the primary endpoint76,272. Correlates of protection have been used 
for licensure in future generations or variants of a licensed product, 
or in instances where direct efficacy against disease is not read-
ily feasible and correlates of protection are well-established. The 
evidence supporting recognition of a correlate of protection may 
be derived from an efficacy trial, which provides the opportunity 
for nested immunogenicity evaluations and detailed analysis of the 
relationship between immune and clinical endpoints. Alternatively, 
as in the case of GBS, immunological correlate of protection may 
be inferred from sero-epidemiological studies.
Correlates of protection have indeed been used for licensure of 
meningococcal, pneumococcal conjugate, and inactivated influenza 
vaccines. Group C meningococcal conjugate vaccine was licensed 
in the United Kingdom based on immunogenicity studies with-
out efficacy data. These compared serum bactericidal assay titers 
induced by the experimental vaccine with a licensed serogroup C 
polysaccharide vaccine, which had an established evidence of effi-
cacy and correlates of protection274,303. The 10-valent pneumococ-
cal conjugate vaccine (PCV10) and the 13-valent pneumococcal 
conjugate vaccine (PCV13) were licensed based on non-inferiority 
trials compared against PCV7 using serological end-points304. Use 
of immunogenicity bridging studies comparing new vaccine prod-
ucts with those with established clinical efficacy is an accepted 
licensure pathway for inactivated seasonal influenza vaccine305,306. If 
licensure is granted based on a primary immunogenicity endpoint, 
there may be a regulatory requirement for post-licensure evaluations 
of effectiveness against disease endpoints. The optimal design of 
post-licensure trials need careful considerations as the inclusion of 
a non-vaccinated study arm may be deemed ethically unacceptable. 
Alternative case control, cluster randomized or ecological studies 
are possible.
Possible study endpoints
Trial with a disease endpoint
GBS disease GBS invasive disease in young infants would likely 
be viewed as a relevant primary efficacy endpoint (see Table 8)76. 
Given that GBS-related stillbirths have similar pathophysiol-
ogy as neonatal GBS disease (ascending infection from a colo-
nizedmother), using a composite disease endpoint that includes 
GBS-related stillbirths is a possibility, which could help reduce the 
study sample size. Subgroup analyses may be used to assess the 
influence of various maternal factors (e.g., HIV infection, malaria, 
malnutrition, maternal age, multiparity) on protection. Factors that 
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influence the extent of protection, such as when maternal vacci-
nation occurs in relation to the birth of the child (allowing suffi-
cient time for a maternal antibody response), the gestational age 
at birth (placental transfer will be less in those born prematurely) 
and the chronological age of the infant (antibody levels will wane 
over the first 2–3 months of life), may also need to be character-
ized76. Analyses of vaccine serotype-specific efficacy and efficacy 
stratified by term vs. preterm, early-onset disease vs. late-onset 
disease, and serotype-specific efficacy could be conducted76. Other 
endpoints of public health interest such as prevention of prematu-
rity, stillbirths, hospitalization, and mortality could be considered 
but interpreted carefully in the context of multiple statistical testing 
and statistical power. See Table 8 for summary of candidate case 
definitions.
Table 8. Possible case definitions for phase III vaccine trial primary and secondary endpoints.
Candidate case definition Pros Cons
Infant invasive GBS 
disease 
 
 
--Early-onset 
 
 
--Late-onset 
 
 
--Young infant
GBS isolated from a normally 
sterile site (e.g., blood, CSF) by 
culture in an infant with PSBI 
 
Onset of invasive GBS disease 
during days 0–6 of life 
 
Onset of invasive GBS disease 
during days 7–89 of life 
 
Onset invasive GBS disease 
during days 0–89 of life
    •  Gold standard clinical endpoint 
    •  GBS isolates can be used to 
further characterize the strains 
    •  Young infant: provides the largest 
number of cases 
    •  Early-onset: Pre-clinical and 
Phase II data suggest efficacy for this 
endpoint may be higher than for late-
onset or a combined endpoint
    •  Low baseline rates 
    •  Requires high capture rate 
of ill babies, in particular on day 
0 of life, for PSBI assessment 
    •  Requires specimen 
collection and access to 
qualified laboratory within a 
short period after case capture 
    •  Blood culture sensitivity 
may be low and varies 
depending on how specimen is 
collected and processed
Probable/possible GBS 
sepsis
Clinical sepsis (see below) 
plus surface colonization with 
GBS and no other sepsis cause 
identified
    •  Higher baseline rates 
    •  Swab specimens may be easier 
to collect and process than sterile site 
specimens
    •  Low specificity for GBS 
disease
Clinical sepsis PSBI: 
Any one of: not feeding well, 
convulsions, fast breathing 
[≥60 breaths/min], severe chest 
indrawing, fever [≥37.5°C], low 
body [<35.5°C] temperature, 
movement only when stimulated 
or no movement at all
    •  Very high baseline rates 
    •  LMIC are familiar with this 
definition 
    •  This definition links to global 
causes of death and verbal autopsy 
data
    •  Very low specificity for GBS 
disease
Premature birth Birth at <37 weeks’ gestation Provides a standardized definition that 
has been widely used
    •  An accurate estimate of 
gestational age is required. 
    •  Not GBS-specific and the 
contribution of GBS is likely low
Stillbirth Baby born with no signs of life at 
or after 28 weeks’ gestation
A definition currently suggested by the 
WHO for international comparison.
    •  An accurate estimate of 
gestational age is required. 
    •  Definition is not specific for 
GBS and GBS only accounts for 
a limited portion of stillbirths
GBS-related stillbirth Stillbirth (as defined above) with 
GBS confirmed by autopsy or by 
culture from a normally sterile site 
(e.g., fetal heart, CSF)
May decrease the sample size if used 
as part of a composite disease end 
point.
Autopsy may not be culturally 
acceptable in certain 
communities. Stillbirth will need 
to occur at facilities that have 
the capacity to perform autopsy.
Maternal and/or young 
infant GBS colonization
Maternal: Positive GBS vaginal 
and/or rectal culture  
Young infant: Positive GBS 
culture from surface swabs (most 
typically umbilicus, nares, outer 
ear)
    •  Moderate baseline rates 
    •  Low complexity with regards to 
specimen collection and processing 
    •  Yields isolates for further strain 
characterization 
    •  Sheds light on vaccine impact on 
carriage
    •  Requires sites to have 
a standardized specimen 
collection and processing 
procedure. 
    •  Knowledge of colonization 
status before delivery may 
necessitate IAP. 
    •  Indirect measurement of 
disease endpoint: a lack of 
reduction of colonization may 
not mean lack of protection 
against invasive infant disease
CSF: cerebrospinal fluid, GBS: group B streptococcus, IAP: intrapartum antibiotic prophylaxis, LMIC: low- and middle-income countries, PSBI: probable severe 
bacterial infection, WHO: World Health Organization
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Colonization Newborn GBS colonization or exposure from colo-
nized mothers is a precursor to GBS disease. The demonstration of 
vaccine efficacy against maternal and newborn colonization may 
argue for a protective effect of GBS vaccination. If vaccination 
reduces vaginal GBS colonization with the targeted invasive strains 
at the time of delivery, the risk of developing early-onset disease 
and potentially late-onset disease by strains targeted by the vaccine 
would likely decrease76. However, other factors may play a role, 
as only a small proportion of colonized neonates develop disease. 
Further considerations on case definitions are provided in Table 8.
Trial with immunologic correlates of protection. For glycocon-
jugate GBS vaccines, evidence from immune-epidemiological 
studies suggest that maternally-transmitted, functional IgG anti-
bodies against GBS capsular polysaccharides, as measured by a 
quality-assured opsonophagocytic assay in serum from neonates 
and/or young infants may constitute a candidate substitute 
endpoint (see immune correlates of protection section). Further 
evidence is needed to evaluate the possible role for immune mark-
ers of protection induced by protein vaccine candidate in the 
licensure pathway.
Considerations for licensure based on immune markers While 
associations between antibody concentrations and risk of disease 
have been observed, the strength and nature of these  associations 
require further investigation and continued assay standardization 
efforts. Several analytical frameworks for validating immune mark-
ers as substitute endpoints for protection against clinical disease 
have been developed274. The Prentice Criteria (see Box 2), origi-
nally designed for randomized-controlled trial data, but extended 
by others to observational designs274, can be used to evaluate poten-
tial substitute endpoints.
The evidence base to evaluate whether a substitute endpoint fulfils 
the Prentice Criteria would most typically come from a trial with 
a clinical disease endpoint and nested immune marker study. For 
a GBS candidate vaccine, evidence for these criteria may need to 
be gleaned from a range of experimental and observational stud-
ies. The first criterion, that protection against the clinical endpoint 
is significantly associated with vaccine receipt, may derive from 
animal challenge studies. Evidence for the second criterion (the 
immune marker is significantly related to vaccination status) would 
likely derive from phase II studies. Evidence for the third (the sub-
stitute endpoint is significantly related to protection against the 
clinical endpoint) would likely derive from sero-epidemiological 
observational cohort and case-control studies. Evidence for the 
fourth criterion may come largely from existing knowledge about 
immune response and protection among young infants in the first 
3 months of life.
The Prentice Criteria are not the only approach to evaluation of 
a substitute endpoint. The Qin framework307 can also be applied. 
This framework distinguishes associations between immune 
markers and clinical disease endpoints into three classes, and within 
these also offers more options for causal inference frameworks that 
can be applied. This framework also highlights whether a substi-
tute endpoint is specific to a single population (the data derived just 
from one population) or whether it is general (meaning it has been 
observed in multiple populations).
Endpoint case definitions
Isolation of GBS from a normally sterile site, such as blood or CSF 
in an infant with possible sepsis or meningitis, is a widely used 
definition for young infant invasive GBS disease22,24,32,37,38,46,146,147. 
GBS isolation by culture is considered the reference standard. 
Automated culture methods yield higher detection rates compared 
to manual culture methods105,308; minimizing time between collec-
tion and inoculation of blood culture bottles, using pediatric bottles 
for young infants, and maximizing blood volumes are important 
for optimal results105. For GBS meningitis, in addition to posi-
tive CSF culture, case definitions have included detection of GBS 
antigens in CSF (e.g., latex agglutination)24,46, detection by PCR46, 
and GBS positive blood culture with CSF findings consistent with 
meningitis22,46,47. As described, onset of disease during days 0–2 
or 0–6 of life is commonly used for early-onset disease and onset 
during days 7–89 is used for late-onset disease3,24,32,38,46,147. Due to 
challenges in surveillance for invasive disease, some young infant 
studies have developed case definitions for probable GBS infection 
capturing infants with clinical sepsis and surface colonization with 
GBS309–311. Because surface colonization of young infants can 
be common, however, such definitions have limited specificity. 
Recently, some studies have used PCR on whole blood in addition 
to blood culture95,312. This can enhance detection but blood samples 
from healthy controls provide an important context: a low percent-
age of healthy controls have been documented with positive PCR on 
blood in both South Africa and South Asia (SANISA and ANISA 
unpublished studies). Another option for newborn disease is clini-
cal sepsis. Several definitions have been used. PSBI, as defined by 
IMCI103 is sensitive but not specific: the sensitivity is estimated 
to be 85% and the specificity of 75% based on an experienced 
pediatrician’s assessment101. South Africa has used a more specific 
definition including both clinical and laboratory signs15. Use of chest 
X-rays may be considered if pneumonia is one of the outcomes 
of interest. Candidate case definitions are summarized in Table 8.
Sample size
The number of young infant GBS cases at single institutions is 
relatively small, depending on the number of annual deliveries and 
the disease incidence rate. A trial with a disease endpoint would 
likely necessitate a multi-center trial. An efficacy trial conducted 
in settings where standards of care include screening-guided IAP 
would lead to very large sample size requirements. If acceptable, 
Box 2. Prentice Criteria for validation of a surrogate endpoint274,328
1.  Protection against the clinical endpoint is significantly related to 
having received the vaccine
2.  The substitute endpoint (immune marker) is significantly related 
to vaccination status
3.  The substitute endpoint is significantly related to protections 
against the clinical endpoint
4.  The full effect of the vaccine on the frequency of the clinical 
endpoint is explained by the substitute endpoint, as it lies on the 
sole causal pathway
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trial conduct in a high incidence setting where screening-based IAP 
is not implemented as standard of care would reduce the sample 
size requirement. Adequate infection risk management in study 
participants would need to be discussed with relevant authorities 
and institutional review boards (IRBs), in consideration of local 
recommendations and WHO recommendations. Acceptability 
may be higher if favorable safety has already been established in a 
significant number of individuals. At a site with an incidence of 
2.0 per 1000 live births for neonatal GBS disease <90 days of age, 
approximately 34–44,000 pregnant women will need to be enrolled 
(assuming that 75–85% of neonatal GBS disease are caused by 
vaccine serotypes, 70–80% are eligible, and 90% power to detect 
vaccine efficacy of 75% against vaccine serotypes), whereas 
>100,000 pregnant women will be needed in countries such as 
Europe and North America where IAP has reduced the incidence 
of early-onset disease to markedly less than 1 per 1000 live births76 
(Table 9. For conjugate vaccines this number will vary depending 
on the GBS serotypes contained in the candidate vaccine and the 
serotype distribution at the study site. A licensure trial based on an 
established immune correlate of protection would require a smaller 
sample size and the total pre-licensure exposed population would 
likely be determined by safety characterization requirements. 
Considerations for safety evaluation are described in “safety con-
siderations” and “regulatory considerations and potential licensure 
pathways for low- and middle-income countries”.
Safety considerations
Evaluation of safety for a vaccine that will be specifically approved 
for use in pregnant women is unique given that: (1) the safety of 
both the mother and the fetus/child will need to be considered, and 
(2) complications of pregnancy may occur even in pregnancies con-
sidered as “low risk” regardless of the vaccination status288. There-
fore, the relative risk of common adverse pregnancy outcomes in 
the study population should be determined. Sample sizes must 
be adequate considering baseline incidence of adverse pregnancy 
outcomes and may not be finalized until phase II safety data are 
available. Detection of rare adverse outcomes require large sample 
size. Baseline studies can be useful to determine sample size needs, 
which should be discussed in advance with regulators.
One of the challenges in assessing safety of maternal immunization 
has been a lack of standard definitions for maternal immunization 
adverse events313. In 2014 WHO held a consultation jointly with 
the Brighton Collaboration to facilitate harmonization of exist-
ing key terms to support monitoring of vaccine safety in pregnant 
women and newborn children314. Key terms were chosen for dis-
cussion based on (1) frequency, (2) severity of health outcome, (3) 
public health relevance, and (4) measurability in different settings. 
The Global Alignment of Immunization Safety Assessment in preg-
nancy (GAIA) established working groups to review the evidence 
from the WHO-Brighton Collaboration landscape analysis, and has 
developed a set of interim case definitions according to the Brighton 
Collaboration process and format315. As of September 2015, the 
working group has developed 10 case definitions currently under-
going peer-review316.
Ethical and standard of care considerations
There is no regulatory or ethical prohibition on studies in 
pregnancy317–319. However, the concept of maternal vaccination, 
which may potentially pose harm to both the mother and the infant, 
may not be well received in countries where uptake of vaccines 
currently recommended for pregnant women by WHO is low320. If 
a randomized-controlled study is designed, an important considera-
tion is whether the control group should receive another vaccine 
that is currently recommended by WHO rather than placebo76.
Controversies exist surrounding whether trials in low- and 
middle-income countries with a high burden of GBS disease should 
offer universal screening and IAP to their participants, the world-
wide “best available” standard of care321. Arguments against this 
have been presented: provision of care that is not sustainable at 
the study site could produce results that are more generalizable in 
higher-income countries and have little social value for the host 
community321. Additionally, provision of a standard of care 
normally not available could coerce pregnant women into trial 
participation. Authors have suggested that study sites should 
adhere to local recommendations, in consideration of WHO 
guidelines100,102,116. The acceptability of a trial under local stand-
ards of care may be dependent on the benefit risk assessment and 
the available safety data on the candidate vaccine. Whatever the 
approach, GCP trials should be authorized and under oversight by 
local IRBs and recognized authorities, with participant agreement 
documented through an informed consent process.
Table 9. Estimated sample size for a phase III randomized 
controlled trial using a clinical endpoint of invasive neonatal 
GBS disease.
Incidence rate of invasive neonatal 
GBS disease  
(per 1,000 live births)
Estimated sample 
size*
0.25  
(Early-onset disease, U.S., 2014)1 275,000–356,000
0.45  
(Early-onset disease, pooled estimate for 
Europe)2 
153,000–198,000
0.73  
(Late-onset disease, pooled estimate for 
sub-Saharan Africa)3
94,000–122,000
1.3  
(Early-onset disease, pooled estimate for 
sub-Saharan Africa)3
53,000–68,000
2.7  
(Overall GBS incidence during ages 0–90 
days , South Africa, 2004–2008)4 
25,000–33,000
* Assuming 90% power to detect 75% vaccine efficacy, 75–85% of disease 
are vaccine types, 70–80% of approached participants are eligible per 
protocol
1. Active Bacterial Core Surveillance, 2014
2. Edmond et al. 20123
3. Sinha et al. 201651
4. Cutland et al. 201547
GBS : group B Streptococcus, U.S.: United States
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Considerations about research center characteristics in 
low- and middle-income countries
Phase III studies with clinical outcomes as endpoints would 
likely need to be conducted in geographical locations with a high 
burden of neonatal invasive GBS disease (Table 9), which are likely 
to be in LMIC. Important trial site characteristics are reviewed in 
Table 10. Important aspects include the presence of experienced 
clinical-trialists and established Ethics Review Committees (ERC) 
and Regulatory Authorities (RA) oversight, to ensure the highest 
compliance with Good Clinical Practice standards76; availability of 
clinical and laboratory infrastructure for optimal capture of PSBI 
cases for specimen collection, processing, and identification of GBS 
from collected specimens105; proportion of home deliveries; access 
to care supportive of rapid clinical sepsis diagnosis and collection 
Table 10. Important characteristics for study sites for GBS vaccine trials.
Characteristic Regardless of endpoint Specific to disease endpoint Specific to immunogenicity 
endpoint
Disease burden     -   Evidence of GBS disease as a 
contributor to neonatal sepsis
    -   country-level interest in GBS vaccine
    -   High baseline rate of 
invasive disease (see 
Table 8, Table 9) despite 
implementation of local 
standard of care 
Knowledge of circulating 
disease-causing 
serotypes
    -   Prior information on maternal 
colonization rates
Location/population     -   Generalizability to LMIC in the primary 
regions targeted for vaccine
    -   General acceptance in the population 
of vaccination and vaccines during 
pregnancy
    -  Oversight by appropriate ERC/RA
    -   Delivery hospital serving 
a defined ANC catchment 
and a large annual 
number of deliveries to 
contribute to achievement 
of sample size targets
    -   Acceptance in the population of 
blood draws from mothers and 
young infants
Laboratory capacity     -   Reliable freezers for appropriate 
storage of specimens related to 
endpoints
    -   Ability and willingness to ship 
specimens out of country for further 
analysis
    -   Capacity to process colonization swabs 
for GBS isolation
    -  Familiarity/training in GCLP
    -   Strong onsite 24/7 blood 
and CSF culture capability 
at the labor and delivery 
hospital and primary 
admission location for ill 
newborns
    -   Availability of automated 
blood culture machines, 
appropriate specimen 
collection bottles, and 
proficiency at bacterial 
isolation and GBS 
identification.
    -   Capacity to perform 
serotyping by 
conventional methods 
or PCR; MLST; whole 
genome sequencing; 
antimicrobial susceptibility 
testing (or ability to ship 
sample to reference 
laboratory)
    -   Laboratory capacity for serum 
separation and aliquoting
    -   Ability to ship specimens 
to designated reference 
laboratory (or ability to perform 
immunogenicity assays onsite)
Recruitment, enrollment 
and maternal vaccination
    -   Ability to reach pregnant women in the 
second trimester of pregnancy and to 
predict reliably where they will deliver
    -   Ability to recruit, screen and consent 
pregnant women according to GCP
    -   Ability to consent a high proportion of 
eligible women for enrollment in the trial
    -   Ability to integrate vaccination and 
specimen collection (blood or swabs) 
into ANC visits
    -   Ability for reliable estimation of 
gestational age
    -   Ability to reach a large 
portion of pregnant 
women in the delivery 
catchment, to allow for 
achievement of sample 
size targets
    -
Birth capture     -   Predesignated clinical facility for 
delivery and study staff on site to 
capture clinical, safety and endpoint 
information or specimens
    -   A medical records system 
that allows for capture of 
salient labor and delivery 
information (for example 
if IAP was administered) 
that may affect endpoint 
interpretation
    -   Ability to capture cord blood 
from a high proportion of 
enrolled delivering women
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Characteristic Regardless of endpoint Specific to disease endpoint Specific to immunogenicity 
endpoint
Endpoint capture     -   A limited number of defined locations 
where study participant deliveries and 
maternal postpartum or young infant 
hospital admissions will take place
    -   24/7 availability of trial 
staff or trained physicians 
on study procedures
    -   An already established 
clinical practice of 
performing septic 
workups when babies 
fulfil IMCI criteria for 
possible serious bacterial 
infection
    -   Capacity to collect lumbar 
punctures from newborns 
meeting possible 
meningitis criteria
    -   Capacity and supplies 
for sterile collection of 
appropriate specimens 
upon onset of illness and 
where possible before 
administration of antibiotic 
therapy
    -   Capacity for real-time 
investigation and 
specimen collection from 
stillbirths
    -   Requirement for chest 
X-rays capacity to be 
considered
    -   Ability to capture repeated 
blood draws from the mother 
and the newborn/young infant at 
pre-designated intervals
Safety monitoring     -   Capacity to follow up enrolled women 
before and after delivery for required 
time periods (six months or more)
    -   Capacity to capture pregnancy and 
birth outcomes including clinical status 
at birth and presence of congenital 
anomalies
    -   Capacity to follow newborns for 
adverse/serious adverse events for 
the required time period (six months or 
more)
    -   Capacity to capture newborn 
developmental measures in addition to 
illness events
    -     -
Local standards of care     -   Antenatal, labor and delivery, 
postpartum and newborn standard 
of care policies consistent with local 
recommendations/WHO guidelines for 
local settings
    -   Standards of care that will be 
supportive for generalization to other 
settings
    -     -
Prior trial experience     -  Prior experience with GCP and GCLP
    -   Prior experience with clinical trials, 
ideally in pregnant women
    -   Track record of ability to implement 
study protocols as part of a multi-center 
trial
    -  Prior experience with vaccine studies 
    -   Prior experience with safety monitoring 
for Phase II and/or Phase III trials
    -   Strong relationship with community and 
experience with social mobilization
    -   Strong relationships with clinical staff 
in pediatric, microbiology and obstetric 
departments
    -   Prior experience with 
invasive GBS disease 
surveillance
    -   Prior experience with 
large-scale studies of 
delivering women and 
newborns
    -   Prior experience with blood 
collection, especially from 
newborns
    -
ANC: antenatal care, CSF: cerebrospinal fluid, GBS: group B Streptococcus, GCP: Good Clinical Practice, GCLP: Good Clinical Laboratory Practice, ERC: 
ethics review committee, IAP: intrapartum antibiotic prophylaxis, IMCI: integrated management of childhood illness, LMIC: low- and middle-income country, 
MLST: multilocus sequence typing, PCR: polymerase chain reaction, RA; regulatory authority
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of appropriate specimens close to disease onset76; capacity to assess 
gestational age, provide sufficient medical care and to identify and 
respond to adverse events in both vaccinated pregnant women and 
their newborn infants76. Clinical management study algorithms can 
support standardized collection of safety events and endpoints of 
interest according to defined case definitions.
Potential challenges. Several review articles have summarized 
challenges in conducting studies that involve pregnant women in 
low- and middle-income countries320,322. Reaching women during 
the early stages of their pregnancy may be challenging in societies 
where women are reluctant about revealing their pregnancy early322, 
and may miss the window of enrollment and vaccine administra-
tion. In addition, accurate estimation of gestational age, which is 
important in assessing pregnancy outcomes (e.g., preterm), is often 
a challenge in resource-limited settings. Measurements that are 
typically used, such as based on last menstrual period or measure-
ment of fundal height, often do not provide consistent results. It is 
important for the participants to deliver their infants at predictable 
locations affiliated with the study and to be able to follow through 
on the follow-up visits to assess study-specific adverse events. 
However, this can be challenging in settings where regular follow-
up visit after delivery is not customary.
Regulatory considerations and potential licensure 
pathways for low- and middle- income countries
The regulatory considerations for products seeking an indication 
for use in pregnant women differ between already-licensed 
products and new products seeking licensure expressly for use 
among pregnant women. While there are several examples of 
already-licensed products with public health recommendations for 
use during pregnancy, there are no products yet that have achieved 
licensure for the specific indication of use during pregnancy. 
Respiratory syncytial virus (RSV) vaccines may represent the first 
pathogen class of vaccines that gain an initial indication for immu-
nization of pregnant women as at least one RSV vaccine is ahead 
of GBS vaccines in their development timelines. Early dialogue 
between vaccine developers and regulators can play a particularly 
important role for maternal immunization product development. 
Major regulatory authorities, as well as the Council for International 
Organizations of Medical Sciences (CIOSM) in collaboration with 
WHO, have agreed that pregnant women should be presumed eligi-
ble for participation in research studies (CIOMS Guideline 17)323, 
and that this applies also to vaccines intended to protect primarily 
the offspring.
Licensure in the United States and Europe can be requested through 
due Food and Drug Administration (FDA) and European Medicine 
Agency (EMA) processes respectively. The Article 58 pathway 
provides a collaborative review framework between the EMA and 
WHO, for products not intended to be used in Europe. Submissions 
can be done as specified by relevant national regulatory authorities 
in LMICs. The African Vaccine Regulatory Forum (AVAREF) is a 
collaborative forum of regulators from different African countries, 
constituted to enable information sharing between African NRAs. 
The Developing Country Vaccine Regulators’ Network (DCVRN) 
may also facilitate steps in regulatory processes in LMICs that are 
members.
Regulatory considerations from the FDA on the clinical develop-
ment of vaccines indicated for use in pregnancy have been presented 
elsewhere288. In addition to evidence to support safety and effec-
tiveness claims, maternal immunization submission packages may 
need to include information on potential immune interference in 
the infant, due to the transfer of maternal antibodies to the vaccine 
antigen or to carrier proteins that may share epitopes with carriers 
used in the infant vaccine series. The role of immunological corre-
lates of protection will need to be clarified, especially with regards 
to the primary licensure. Relevant quality-assured immunogenicity 
endpoints may also be used to bridge across populations, for 
instance when considering generalizability across LMIC or between 
LMIC and resource-rich settings.
Safety evaluations would be conducted considering vaccine 
effects on both pregnant women and their infants, taking into 
account background rates of common pregnancy complications 
(e.g., pre-eclampsia, miscarriage/spontaneous abortion, stillbirth, 
preterm delivery). Pregnancy and neonatal outcomes, serious 
adverse events, new onset maternal medical conditions. The dura-
tion of safety follow-up for pregnant women and for newborns needs 
to be determined. Phase II data may be needed for optimal determi-
nation of Phase III sample size requirement for safety evaluation. 
Multiple factors including accumulated safety data associated with 
the product to date, safety signals, and the overall benefit to risk 
ratio assessment would likely be taken into account324. See previ-
ous section for considerations on safety in phase III trials. Lastly, 
the need for post-approval investigations should be reflected on. 
To maximize chances of success for a candidate vaccine, vaccine 
developers should plan ahead to overcome potential post-approval 
obstacles325. Target product profiles (TPP) list desirable character-
istics, features, and attributes of a candidate vaccine, and have been 
long used by biotechnological and pharmaceutical companies326.
Areas for future research
We briefly summarize some of the leading scientific gaps rel-
evant to GBS vaccine development and areas for future research 
based on the section topics addressed in this briefing document 
(Table 11).
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Table 11. Gaps and areas for future research.
Briefing document section Gaps and areas for future research
Diseases and sequelae caused by 
GBS and population at risk
Young infant disease epidemiology 
    •  Preterm contribution to young infant disease burden, particularly in low-income countries 
(LIC) where preterm survival may be lower 
    •  Late-onset disease epidemiology in LMIC 
        ○  Understanding how this differs from that described in high-income countries (HIC) 
(proportion preterm, ratio of early to late-onset disease, median age of onset, role of maternal 
HIV infection) 
    •  Role of SES, urbanization, and birth location (facility type, home vs facility) in GBS disease 
risk
GBS disease burden and serotype 
distribution
Young infant disease burden 
    •  Relationship between maternal colonization and young infant disease burden and 
serotype distribution 
    •  More information on burden from South Asia, Eastern Mediterranean Region, and South 
America 
    •  Sub-Saharan Africa: representation beyond southern Africa 
        ○  Areas with low maternal HIV 
        ○  LIC 
    •  More evidence on disease burden from other high mortality regions 
    •  Limited serotype data from LMIC, especially LIC 
 
Pregnancy-associated disease burden 
    •  Limited information from LMIC 
 
Stillbirth burden 
    •  Need for a standardized definition 
    •  Causes of stillbirth are not routinely collected in many countries 
    •  Challenges in obtaining appropriate specimens 
 
Non-pregnant adults 
    •  Limited information from LMIC
Diagnosis and treatment of GBS 
disease
GBS disease diagnosis 
    •  Diagnostic tests that are more sensitive than blood/CSF cultures, with high specificity (not 
positive in healthy infants) 
 
Stillbirth 
    •  An understanding of the right specimen criteria or tests to distinguish presence of GBS 
(colonization) from causal role of GBS in fetal demise 
 
See also Considerations for a phase III trial on case definitions and standards of care
Prevention of perinatal GBS disease 
through intrapartum antibiotic 
prophylaxis
Limited information on the feasibility and challenges in IAP implementation in LMIC (see also 
section Considerations for a phase III trial on standards of care)
GBS vaccine development Number and timing of maternal vaccination, considering successive pregnancies 
    •  In relation to transplacental transfer of maternal antibodies 
    •  In relation to optimizing protection against young infant disease 
 
GBS vaccine antigen that would confer broader protection 
    •  common protein antigen 
    •  higher-valent glycoconjugate vaccine 
 
Defining dose level and options for adjuvantation if needed 
 
Immune correlates of protection 
    •  Need larger sero-epidemiologic evidence base that includes diversity in patient 
populations (e.g., LIC, preterm, mothers with underlying conditions) 
 
Assay standardization, qualification, validation 
    •  Role of functional antibodies
Cost-effectiveness evaluation Limited assessment for LIC (one for sub-Saharan Africa in progress) 
 
Further define needs and opportunities in HIC and GBS vaccination outside pregnancy
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Briefing document section Gaps and areas for future research
Mathematical modeling related to GBS 
vaccines
In general, only a limited number of mathematical modeling conducted to date. Mathematical 
modeling on the following might be helpful: 
    •  Impact of maternal vaccination timing on the preventable portion of young infant disease 
    •  Predicting vaccine impact if vaccine reduces acquisition of GBS colonization with 
vaccine-included serotypes 
    •  Predicting the potential impact of maternal immunization across LMIC settings with 
different prevalence in underlying conditions (e.g., HIV) 
    •  Potential impact on GBS-related stillbirth and preterm delivery
Considerations for a phase III trial Evaluation of validity of candidate substitute endpoints 
 
Study endpoints and case definitions 
    •  Development of agreed case definitions for disease endpoints, standard data collection 
methodologies 
    •  Define the role of colonization studies, consider possibility of strain replacement 
 
Define sample size requirements for safety 
 
Acceptability of local standards of care in context of a trial
Regulatory considerations ad potential 
licensure pathways for low- and 
middle-income countries
More clear indications from regulators on acceptable licensure pathways for maternal GBS 
vaccine, particularly with regards to use of substitute endpoints for primary licensure, and with 
regards to generalizability across the different settings where vaccine maybe used
CSF: cerebrospinal fluid, GBS: group B Streptococcus, HIV: human immunodeficiency virus, HIC: high-income countries, IAP: intrapartum antibiotic prophylaxis, 
LIC: low-income countries, LMIC: low- and middle-income countries, SES: socioeconomic status
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Having personally published earlier this year on GBS vaccination , this is the most comprehensive review
of GBS vaccination I have seen. Quite appropriately, the authors have extended the review beyond early
onset GBS disease to include late onset GBS disease and GBS disease in non-pregnant adults.
Unlike many reviews they have focused on low and middle-income countries (LMIC) where the burden of
disease is at its greatest whereas most of the available data are from resource rich countries.
In addition, the review covers other important topics often omitted from other overviews such as the
increased risk of neonatal GBS disease in HIV-positive mothers, the use of protein based vaccines,
reverse vaccinology and the necessary use of surrogate endpoints in vaccine trials.
Importantly, they have addressed the problem that logistically, because of the estimated sample size for a
phase III randomised controlled trial using a clinical endpoint of invasive neonatal disease, the different
burden of disease across geographic regions dictates that trials may have to be performed in LMICs. This
has its own problems, not the least of which is the acceptability of local standards of care in the context of
such a trial.
Finally, a minor criticism would be the omission of a discussion on the association between black race
and GBS rectal colonisation, which is particularly pertinent bearing in mind the burden of disease in Africa
and in African American women in the USA. In addition, while the use is mentioned, the role of rapid
detection of GBS carriage using automated PCR techniques that might decrease the unnecessary use of
intrapartum antibiotic prophlyxis during labour merits some emphasis.
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This manuscript, in a logical and practical way, lays out the case for further development and testing of a
GBS vaccine to be given to mothers primarily for the protection of their neonates.
The burden of maternal and neonatal disease is thoroughly discussed and highlights the paucity of
epidemiological data in many resource limited settings. This is the critical data needed to determine the
contribution of GBS to overall neonatal morbidity and mortality in low and middle income countries where
a candidate vaccine is most likely to be beneficial.
There is an excellent list and discussion of previous GBS vaccine trials and outcomes. Even more useful
is the discussion of challenges going forward with GBS vaccine trials, including a review of potential trial
endpoints, challenges of any maternal vaccination program, and potential ethical and regulatory hurdles.
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